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ABSTRACT 
Ventricular dysfunction and dilated cardiomyopathy (DCM) develop among 
untreated HIV-infected people at much higher rates than among HIV-negative 
individuals, resulting in significant contributions to morbidity and mortality. Mechanisms 
underlying development of HIV-associated cardiomyopathy (HIVCM) are as yet poorly 
understood. The well-characterized simian immunodeficiency virus (SIV) model of HIV 
infection provides a unique context for HIVCM pathogenesis studies in that SIV-infected 
rhesus monkeys develop myocardial lesions and contractile dysfunction similar to those 
described in HIV-infected people, suggesting a shared disease mechanism. 
Lymphocytic myocarditis is a commonly reported finding in AIDS patients at 
autopsy and constitutes one of several conditions known to predispose to development of 
DCM, irrespective of HIV-infection status. As lymphocytic myocarditis also occurs with 
high frequency among SIV-infected rhesus monkeys, a retrospective analysis of rhesus 
monkey cardiac tissue collected at necropsy was performed to examine viral and cellular 
correlates of lymphocytic inflammation within myocardial tissue. One subpopulation of 
macrophages, which has been reported by other groups to be associated with an anti-
inflammatory phenotype, was found to correlate inversely with lymphocytic infiltration 
and positively with numbers of virus infected cells, suggesting effects of an anti-
inflammatory cytokine production profile. 
In contrast, the detrimental effects of inflammatory cytokines on myocardial 
structure and function are well-recognized and HIV infection in general is characterized 
by chronic immune activation and inflammatory cytokine dysregulation. To further 
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investigate a role for myocardial cytokine production in development of HIVCM, a 
prospective study was conducted in which SIV-infected rhesus monkeys and uninfected 
controls were treated with recurrent administration of inactivated Mycobacterium avium 
complex bacteria (MAC). SIV-infected, MAC-treated animals rapidly developed 
significant ventricular systolic dysfunction and chamber dilatation not seen in control 
groups, suggesting an exaggerated myocardial sensitivity to exogenous antigenic 
stimulation. Concurrent treatment with the TNFα antagonist etanercept completely 
abrogated development of these changes, strongly implicating a causative role for TNFα 
in evolution of the contractile dysfunction and chamber remodeling. 
 Findings reported from the current studies suggest that characteristics of local 
myocardial macrophage populations and the myocardial tissue cytokine milieu may play 
more important roles than lymphocytic infiltration, cardiomyocyte damage, or viral 
proteins in the pathogenesis of HIVCM. 
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CHAPTER I 
 
GENERAL INTRODUCTION 
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 1.1 Human Immunodeficiency Virus and Cardiac Disease 
Currently, an estimated 33.2 million people world-wide are infected with the human 
immunodeficiency virus (HIV), with 2.5 million new infections and 2.1 million deaths 
from AIDS in the year 2007 alone [1]. Cardiac abnormalities develop at high frequency 
in chronically HIV-infected individuals in the absence of antiretroviral therapy, a fact 
which has been recognized since the early years of the epidemic [2-27]. The spectrum 
and epidemiology of cardiac disease in HIV infection have been extensively reviewed 
[28-42], with development of ventricular dysfunction and dilated cardiomyopathy (DCM) 
being of particular clinical significance and occurring among HIV-infected people at 
much higher rates than among HIV-negative individuals [28, 30, 37, 38, 43-46]. A high 
prevalence of cardiac disease has been documented in HIV-infected populations in sub-
Saharan Africa as well as in the developed world [30, 43, 47-49], and heart disease 
appears to be a particularly significant contributor to morbidity and mortality in HIV-
infected children, where even mild alterations in left ventricular mass or myocardial 
contractility are independently and significantly associated with shortened survival [37, 
48, 50-57]. While subclinical manifestations of HIV-associated cardiomyopathy 
(HIVCM) appear to be relatively common, median survival for HIV-infected individuals 
with DCM is significantly reduced compared to HIV-infected individuals without cardiac 
dysfunction at similar stages of infection, or HIV-negative individuals with idiopathic 
DCM  [19, 58]. While the advent of highly active anti-retroviral therapy (HAART) has 
dramatically improved the lives of many HIV-infected people and recent reports suggest 
that its use may have decreased the frequency of HIV-associated myocardial disease, 
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roughly 80% of those in need of anti-retroviral drugs globally still do not have access to 
them [59, 60]. Furthermore, a recent large clinical trial demonstrated significant increases 
in the incidence of major cardiovascular disease in HIV-infected people who experienced 
CD4+ count-guided interruptions in antiretroviral therapy as compared to those on 
continuous therapy, implicating a continued role for HIV infection in development of 
heart disease which readily reemerges with breaks in therapy [61]. 
The pathogenesis of cardiomyopathy in HIV infection is poorly understood and likely 
involves a combination of host, viral, and environmental factors [62-66]. A variety of 
possible etiologies have been postulated (Table 1.1), with potential mechanisms including 
tissue damage resulting from lymphocytic myocarditis, an inflammatory process which 
has been documented at high frequencies in HIV-infected people at later stages of disease 
progression and which constitutes one of several conditions known to predispose to 
development of DCM irrespective of HIV-infection status [6, 8, 11, 13, 14, 18, 63] 
(reviewed in [67-70]). Numerous studies have attempted to draw connections between the 
lymphocytic myocarditis seen in HIV-infected individuals and development of significant 
myocardial contractile dysfunction, both with and without concurrent chamber dilatation 
[5, 6, 8, 11, 12, 20, 27].  Inflammatory infiltrates in HIV-associated myocarditis are 
consistently documented as comprised predominantly of CD8+ T cells with variable 
numbers of macrophages [12, 13, 18, 27, 71].  Myocarditis in HIV infection is itself 
frequently of unknown etiology, with many studies identifying an underlying pathogen in 
only a minority of cases, though cytomegalovirus, adenovirus, coxsackievirus B3, 
Epstein-Barr virus, Toxoplasma gondii, Mycobacterium avium complex, Candida spp., 
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Cryptococcus neoformans,  Coccidiodes immitis, Histoplasma capsulatum, Aspergillus 
spp., and Pneumocystis jiroveci have all been documented [8, 11, 13, 14, 18, 27, 41, 58, 
72-74].  
A further important potential contributor to development of HIVCM is 
proinflammatory cytokine excess resulting from effects of HIV-associated cytokine 
dysregulation [58, 75, 76]. As discussed below, the myocardium is quite sensitive to 
proinflammatory cytokine effects, which are uniformly cardiodepressant with chronic 
exposure, and associated with substantial pathologic remodeling (reviewed in [77] and 
[78]).  As chronic immune activation and cytokine dysregulation are prominent features 
of HIV-infection [79-83], and local myocardial inflammatory responses have the 
potential to further augment a proinflammatory cytokine milieu, a role for cytokine-
induced myocardial pathology in HIV-infection must be seriously considered [75].  
In evaluating whether HIV itself may play a direct role in induction of local 
myocardial inflammatory responses, contractile dysfunction, or pathologic remodeling, 
multiple investigators have detected HIV viral genome and/or viral proteins in the hearts 
of HIV-infected people [13, 27, 71, 84-87]. Numbers of intramyocardial virus-infected 
cells are consistently very low, however, and in many hearts are undetectable [12, 13, 27, 
71, 72, 84, 87]. Investigators using methods with a high degree of morphologic 
discrimination at the tissue level have in almost all cases found productive HIV infection 
to be restricted to cells within the myocardial interstitium, most consistent with 
macrophages and T cells, such that previous longstanding controversy over the potential 
for HIV to directly infect cardiomyocytes has largely been resolved [13, 71, 87]. In 
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further support of the inability of HIV-1 to infect cardiomyocytes, experimental attempts 
to infect fetal human cardiomyocytes using a wild-type HIV isolate derived from a case 
of pediatric AIDS with severe cardiomyopathy proved unsuccessful, though a VSV 
pseudotyped HIV-1 based vector demonstrated high efficiency infection of these same 
cells [88]. The rarity of HIV genome in myocardial tissue of HIV-infected people 
combined with a failure of the presence or absence of HIV-infected cells to correlate with 
the presence of inflammatory infiltrates or clinical cardiac disease suggests that direct 
infection of cells within the myocardium is unlikely to play a signficant role in the 
pathogenesis of HIV-associated cardiac disease, though this has remained controversial 
[84, 86].  
Further possible contributors to development of HIV-associated cardiac disease 
include myocardial effects of viral proteins [89-94], cardiac autoimmunity [95], drug-
related cardiotoxicities [29, 96-100], autonomic dysfunction [101-106], and micronutrient 
deficiencies, particularly in the context of wasting or chronic diarrhea [36, 43]. 
 
1.2 Cytokines and the Pathogenesis of HIV-associated Cardiomyopathy  
 Inflammatory cytokine-induced myocardial dysfunction is a well-documented 
phenomenon in multiple experimental models, is a significant contributor to 
hemodynamic compromise in sepsis, and may play a significant contributory role in 
development and progression of heart failure regardless of initiating etiology [77, 78, 
107-116]. Roles for inflammatory cytokines in cardiac dysfunction have received 
extensive attention in association with their cardiodepressant effects, demonstrated 
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contributions to myocardial remodeling, and frequent systemic elevations in the context 
of heart failure [77, 78, 115-125]. The mechanisms by which inflammatory cytokines 
generate their effects in the myocardium have been studied in some detail. Cytokine-
induced products of the sphingomyelinase pathway, nitric oxide generated by inducible 
nitric oxide synthase (iNOS), and reduced cyclic AMP response to β-adrenergic 
stimulation all appear to act as mediators of cardiodepressant effects [77, 108, 109, 126-
128]. On a molecular level, these effects result from modulation of intracellular calcium 
transport, antagonism of cyclic AMP-mediated Protein Kinase A effects, alteration of 
sensitivity of myofilaments to calcium binding, S-nitrosylation of thiol residues on 
contractile proteins, functional uncoupling of β-adrenergic receptor stimulation from 
adenylyl cyclase activity, and possibly alteration of β-adrenoreceptor internalization 
kinetics (reviewed in [77, 108]), [127].  
Inflammatory cytokine-induced pathologic remodeling yields chamber dilatation, 
myocardial hypertrophy, and fibrosis attributable to dysregulation of matrix 
metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) balances, 
increased expression of TGFβ, alterations in susceptibility to cardiomyocyte apoptosis, 
and stimulation of hypertrophic and fetal gene expression patterns [125, 128-132]. 
Experimental work in rodent models demonstrates TNFα to be strongly associated with 
pathologic remodeling, and pharmacologic antagonism of TNFα in human cardiac 
transplant recipients significantly decreases allograft hypertrophy and fibrosis, 
strengthening the implication that TNFα plays an important role in pathologic 
remodeling in vivo in humans, as well as in animal models [129, 130, 133, 134].  
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Transgenic mice with myocardial expression of TNFα comprise the most 
thoroughly studied model of inflammatory cytokine excess on the heart. These animals 
develop severe biventricular dilatation, heart failure, and premature death, with the 
rapidity of disease development dependent on gene dose [129, 134]. And while 
inflammatory cytokine excess as a primary effector has well-demonstrated adverse 
myocardial effects, circulating levels of inflammatory cytokines are also often 
secondarily elevated in humans with heart failure, a fact which may contribute to heart 
failure progression (reviewed in [78, 111, 135]).  The degree of circulating cytokine 
elevation in heart failure patients has been demonstrated to correspond to New York 
Heart Association (NYHA) functional classifications of heart failure severity [117-119, 
136, 137], and measures of myocardial systolic function [138]. Supporting a role for 
elevated circulating inflammatory cytokines in heart failure progression, healthy rats 
subjected to 15 days of continuous TNFα infusion to generate circulating levels in the 
range found in humans with end-stage chronic heart failure developed significantly 
depressed ventricular function and ventricular dilatation with structural remodeling [130].  
HIV-infection is intrinsically characterized by chronic immune activation and 
cytokine dysregulation [79-83, 139]. Exaggerated levels of inflammatory cytokine 
production by HIV-infected leukocytes or leukocytes derived from HIV-infected persons 
have been reported by multiple investigators and elevated circulating levels of TNFα and 
other proinflammatory cytokines have been documented at all stages of HIV infection 
[140-148]. These elevated levels do not appear to normalize in the face of HAART, and 
in some reports may rise after initiation of therapy [143, 146, 149, 150].   
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Numerous features suggest the likelihood of a substantial role for inflammatory 
cytokines as mediators of HIVCM. The local myocardial tissue environment has been 
demonstrated to be a rich potential source of inflammatory cytokines, with both 
cardiomyocytes and locally resident non-myocyte interstitial cell populations competent 
to produce a variety of inflammatory mediators, and heart tissue capable of generating as 
much or more TNFα per gram of tissue in response to endotoxin stimulation as liver or 
spleen [122, 126, 151-155].  Non-myocyte populations comprise up to 70% of the total 
cellular constituency of the myocardium and consist of a mixed assemblage of cell types, 
including substantial populations of dendritic cells and macrophages which can serve 
directly as targets of HIV infection [151, 156-161]. This environment represents a 
volatile setting in the context of HIV-infection. 
 
1.3 Existing Experimental Support for a Role for Cytokines in HIVCM 
Experimental work designed to examine the role of inflammatory cytokines in the 
pathogenesis of HIVCM has been limited; however, one group has demonstrated 
significantly increased myocardial TNFα immunostaining signal intensity in HIV-
infected individuals with DCM as compared to non-HIV-infected individuals with DCM, 
suggesting a role for TNFα in the HIV-associated disease process [58]. Several studies in 
murine models have gone farther, drawing connections between specific HIV proteins 
expressed in CD4+ cell contexts and development of cardiac disease. Transgenic mice 
expressing HIV-1 nef protein exclusively in CD4+ cells develop cardiac disease despite 
the presence of low numbers of HIV-1 transgene-expressing cells in the heart, and the 
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lack of a significant correlation between cardiac lesion development and levels of 
expression of the HIV-1 transgene [91]. HIV-1 transgene expression exclusively in CD4+ 
cells with low numbers of transgene positive cells in the heart mimics the distribution 
seen with natural HIV-1 infection and implicates an indirect, HIV-protein induced effect 
on levels of soluble mediators as cause of the myocardial injury. Similarly, cardiac 
disease has been generated in transgenic mice expressing simian immunodeficiency virus 
(SIV) nef protein exclusively in CD4+ cells [162].  
 
1.4 A Role for Myocardial Macrophages  
Macrophages and dendritic cells constitute cell types widely distributed 
throughout peripheral tissues including the myocardial interstitium, where they may be 
found in significant numbers [156, 157, 163-166]. These populations serve as sentinels of 
the innate immune system, sensitizing the adaptive immune system through antigen 
presentation, and significantly modulating immune responses through cytokine 
production [161, 167]. Due to expression of the appropriate receptor and co-receptors, 
both macrophages and dendritic cells may serve as direct targets of HIV infection, and 
display a variety of functional abnormalities in HIV-infected individuals, including 
elevated secretion of inflammatory cytokines, both constitutively and upon stimulation 
[80, 141, 142, 145, 148, 160, 161, 168].  Furthermore, in rodent models, dendritic cells 
have been demonstrated to serve as a critical link between cardiotropic viral infections 
and subsequent autoimmunity against myocardial antigens [169], and macrophages have 
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been identified as the major effector population in at least one model of myocardial 
autoimmunity yielding dilated cardiomyopathy, heart failure, and death [170]. 
As macrophage and dendritic cell populations are well-represented in the 
interstitial tissues of the myocardium and have been demonstrated to show significant 
dysregulation of function and inflammatory cytokine production in the context of HIV 
infection, they have strong potential to contribute to development of HIV-associated 
myocardial pathology. Increased levels of myocardial macrophage infiltration have been 
documented in human cases of HIVCM, as well as in a murine model of AIDS with 
associated cardiomyopathy [71, 171]. HIV-infected perivascular macrophages have been 
found in some instances to be associated with apoptosis of surrounding cardiomyocytes 
[94], with significant correlations present between extent of apoptosis and both TNFα 
expression and expression of the HIV viral protein gp120 [71, 94]. In addition, 
associations between extent of myocardial macrophage involvement and development of 
cardiac functional decline have been identified prospectively in a murine model of AIDS 
[171]. 
While in many contexts the actions of macrophage and dendritic cell populations 
contribute to development of inflammatory responses, in other contexts their effects may 
be tolerogenic or overtly anti-inflammatory, with the differences between these scenarios 
attributable to differences in the phenotypic subsets of cells involved [167, 172, 173].  
Immature dendritic cells have been associated with induction of peripheral tolerance, for 
instance, and non-classically activated macrophages have been associated with a variety 
of functional roles, including immunosuppression, tissue repair, and angiogenesis 
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(reviewed in [167, 172-175]). While phenotypically diverse, some subsets of non-
classically activated macrophages are typified by ineffective microbicidal activity and 
cytokine secretion profiles characteristically dominated by IL-10, TGFβ, and IL-1RA  
[167, 172-175]. Because of this, characterization of phenotypic subtypes of these cells in 
tissue has the potential to cast light on how specific subpopulations might serve either 
injurious or protective roles dependent on the particular properties of the populations 
involved. In addition to modulation of immune responses through cytokine production, 
the density, distributional characteristics, and activation phenotype of professional 
antigen presenting cells within the myocardium could well be expected to play a role in 
sensitization of the adaptive immune system to both native and exogenous antigens, a 
function which may be protective, but also has the potential to be detrimental in a tissue 
with minimal to no regenerative capacity and strictly limited functional reserve. 
 
1.5 The Simian model of HIV-associated Cardiac Disease 
Study of the pathogenesis of HIVCM in humans is limited by many factors.  
Identifying the earliest time points of development of myocardial pathology and placing 
them within the natural history of HIV infection is generally not possible; complex, 
variable, and potentially toxic medication regimens are routinely used; substantial 
variation can exist in environment and lifestyle among patients; and ethical constraints 
place strict limits on the types of sampling which may be conducted. The simian 
immunodeficiency viruses (SIV) share a close phylogenetic relationship with HIV-1 and 
induce a fatal immunodeficiency syndrome in Asian macaques that provides an important 
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model system for HIV pathogenesis studies [176, 177]. No other model system so closely 
recapitulates the interplay of virus with the immune system and consequent disease 
development seen in HIV-infection of humans. In order to study the pathogenesis of end-
organ dysfunction resulting from direct or indirect effects of chronic HIV infection, 
particularly effects that may result from early insults during the period of acute viremia 
and initial immune containment of the virus, use of an animal model is essential. The SIV 
model of HIV-infection and AIDS is well-established and provides a strong context for 
study of HIV cardiomyopathy in that myocardial functional abnormalities and histologic 
lesions similar to those documented in HIV infection are frequently seen in SIV-infected 
rhesus monkeys (Macaca mulatta), suggesting a shared disease mechanism [178, 179]. 
The SIV cardiomyopathy model was pioneered at the New England Primate Research 
Center (NEPRC), where frequent development of DCM among chronically SIV-infected 
animals was first demonstrated, establishing the utility of the model [178].  
 
1.6 Chronic SIV infection and Simian AIDS are Associated with Dilated 
Cardiomyopathy 
 Significant cardiac dysfunction and myocardial pathology have been 
demonstrated in animals chronically infected with pathogenic strains of SIV [178]. 
Among fifteen rhesus monkeys infected ≥18 months, six infected with pathogenic strains 
of SIV and 9 infected with non-pathogenic clones of SIVmac239 containing deletions of 
the nef gene (SIVmac239Δnef), animals chronically infected with pathogenic strains 
demonstrated significant decreases in global left ventricular systolic function over time as 
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indicated by marked decreases in left ventricular ejection fraction (LVEF: 43±7% 
(pathogenic) versus 61±3% (non-pathogenic)) and evidence of left ventricular dilatation 
through increases in both left ventricular end-systolic volume indices (ESVI: 16±3 
mL/m2 (pathogenic) versus 9±1 mL/m2 (non-pathogenic)) and left ventricular end-
diastolic volume indices (EDVI: 28±3 mL/m2 (pathogenic) versus 21±3 mL/m2 (non-
pathogenic)) [178]. In contrast to chronically infected animals, changes were not detected 
in an acute infection cohort of 16 age-matched young adult rhesus monkeys infected with 
either pathogenic SIVmac239 or non-pathogenic SIVmac239Δnef [178]. These animals, 
followed over a 5 week course of infection with weekly M-mode and 2D 
echocardiography, did not develop significant changes from baseline values, though 
animals infected with SIVmac239 did experience decreases in CD4+ T cell count 
consistent with effects of early pathogenic infection [178]. Furthermore, of 24 rhesus 
monkeys that died of simian AIDS in this study, 9 demonstrated myocarditis, with 
infiltrates consisting predominantly of CD3+ cells with smaller numbers of CD68+ 
macrophages. These results, which are consistent with common descriptions of the time 
course and character of cardiac pathology in HIV-infected people, suggest that the source 
of myocardial injury in HIV infection is one that either acts gradually over a prolonged 
period of time, or appears only relatively late in infection.  
Further work evaluating possible correlates of ventricular dysfunction in chronically 
SIV-infected rhesus monkeys has demonstrated induction of myocardial TNFα by 
immunohistochemistry and Western blot in animals that have histologically demonstrable 
myocardial inflammatory infiltration [180]. Quantified TNFα levels were found to have a 
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significant inverse correlation with left ventricular ejection fraction (LVEF), linking the 
elevation in TNFα to decreased ventricular systolic function in this model [180]. 
 These data were among the first to indicate that the SIV-infection model is 
associated with substantial myocardial dysfunction in later stages of infection, that this 
dysfunction appears to be common, and that elevations in myocardial TNFα in the 
context of SIV-infection may be sufficiently severe as to play a role in depression of 
ventricular systolic performance. These findings lay the groundwork for use of the SIV-
infection model to explore in vivo pathogenesis of HIV-associated cardiac dysfunction. 
 
1.7 Rationale and Objectives  
In the reported studies, potential viral and non-viral contributors to development 
of myocardial dysfunction and correlative microscopic pathology in the simian model of 
HIV infection are investigated using a combination of prospective and retrospective 
analyses.  
 As lymphocytic myocarditis is a commonly reported finding both in AIDS 
patients and chronically SIV-infected rhesus monkeys and constitutes one of several 
conditions known to predispose to development of DCM irrespective of HIV-infection 
status [68-70], initial retrospective studies focused centrally on a role for myocardial 
inflammation in evolution of cardiac pathology in SIV-infected animals, evaluating 
inflammation frequency, extent, and character, as well as determining viral, cellular, and 
histomorphologic correlates of these inflammatory infiltrates. Findings in initial work 
identified subpopulations of myocardial macrophages whose numbers correlated 
   15
inversely with lymphocytic infiltration and positively with numbers of virus infected 
cells, suggesting a role for these populations in modulation of the inflammatory response. 
The question of a role for myocardial cytokines in development of myocardial functional 
and structural pathology was then pursued directly in a group of longitudinally evaluated 
cohorts in an acute infection, augmented immune activation model. Use of a prospective 
model allowed monitoring of cardiac function by serial echocardiography with 
concurrent examination of circulating cytokine and chemokine levels, as well as post-
mortem assessment of cytokine levels and histomorphologic features of myocardial 
tissues to determine features correlating most closely with development of contractile 
dysfunction and chamber dilatation in SIV-infected animals.  
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Table 1.1  Possible Etiologies and Associations of HIV-Associated Cardiomyopathy* 
 
Possible Etiologies: 
Drug-related:  Zidovudine, Interferon, Foscarnet, Doxorubicin, IL-2 
 Amphotericin B, Cocaine 
Infectious:   HIV, Toxoplasma gondii, Coxsackievirus group B, Epstein  
    Barr Virus, Cytomegalovirus, Adenovirus 
Metabolic/Endocrine:  Anemia, Thyroid hormone related, Growth hormone 
related, Adrenal insufficiency, Hyperinsulinemia 
Nutritional Deficiency: Selenium, B12, Carnitine 
Cytokine-mediated:  TNFα, Nitric oxide, TGFβ, Endothelin-1 
Autoimmunity:  Anti cardiac myosin, Anti cardiac C protein 
Autonomic Dysregulation: Cardiovascular sympathovagal dysfunction 
 
Associations:  
Encephalopathy, Immunodeficiency (CD4 count < 100), Length of immunosuppression, 
HIV viral load 
 
*Table modified from [64] 
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CHAPTER II 
 
SIV-ASSOCIATED MYOCARDITIS: VIRAL AND CELLULAR CORRELATES OF 
INFLAMMATION SEVERITY 
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ABSTRACT 
Myocarditis is a common finding in HIV-infected people. Cardiac inflammatory lesions 
and functional abnormalities similar to those documented in HIV infection are frequently 
seen in SIV infection of rhesus monkeys, suggesting a shared disease mechanism. A 
retrospective analysis of cardiac tissue collected at necropsy was performed to assess 
correlates of myocardial inflammation in SIV-infected rhesus monkeys. Intramyocardial 
SIV-infected cells were identified in 7 of 21 hearts from SIV-infected animals, with viral 
protein consistently colocalizing with the macrophage marker HAM 56. Productively 
infected cells occurred in low numbers, and did not correlate with presence or quantity of 
inflammation or necrosis.  Intramyocardial CMV was identified in 6 of 21 hearts from 
SIV+ animals, but also did not correlate with presence or quantity of inflammation or 
necrosis. In contrast, T cell infiltration correlated inversely with DC-SIGN+ cell numbers, 
which occurred in significantly higher numbers in SIV+ animals with histologically 
normal myocardium than in SIV+ animals with active or borderline myocarditis or in 
uninfected controls (P < 0.001), suggesting an important immunoregulatory role for this 
population within the myocardium.
Introduction 
  Cardiac abnormalities are common in human immunodeficiency virus (HIV) 
infection, with progression to clinical disease and cardiac death documented in a small 
but significant proportion of cases [5-7, 17, 20, 27, 34, 41, 53].  Myocarditis is one of the 
most frequently recognized findings in HIV-infected individuals, with incidence rates as 
high as 52% reported [6, 8, 11, 13, 72]. While the connection between HIV-associated 
myocarditis and clinical cardiac disease is still unclear given that the majority of cases are 
subclinical, there is considerable evidence to suggest the possibility of a contributory role 
[5, 6, 8, 11, 12, 20, 27]. The etiology of the inflammatory response in this condition is 
poorly understood.  The presence of HIV-infected cells within the myocardium of some 
HIV-infected individuals has repeatedly been documented [18, 27, 84-86, 94], but the 
ability of HIV to infect cardiomyocytes remains controversial [13, 63, 71, 88], as is the 
potential relationship of intramyocardial HIV-infected cells to development of cardiac 
pathology [12, 13, 72, 84, 86]. Other opportunistic and general cardiotropic pathogens are 
identified with variable frequency, in most instances accounting for a minority of cases 
[8, 11-14, 18, 20, 27, 72, 74]. Cardiac autoantibodies have been detected with relatively 
high frequency in HIV-infected individuals with myocardial disease, suggesting a 
possible role for autoimmunity [95]. Drug-related cardiotoxicities may also play a role in 
some cases [34, 99, 100]. 
 Simian immunodeficiency viruses (SIV) are lentiviruses which are genetically 
closely related to HIV and represent the original sources from which both HIV-1 and 
HIV-2 derived [176, 177]. SIV infection of Asian macaque species produces a fatal 
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immunodeficiency syndrome with properties of disease progression very similar to those 
seen in humans with HIV infection [181-186]. The SIV model of AIDS is well-
established, and provides a strong context for study of HIV-associated myocarditis and 
cardiomyopathy due to the occurrence of cardiac morphologic and functional 
abnormalities similar to those described in HIV infection [178, 179]. Use of an animal 
model allows minimization of many confounding factors which accompany study of 
naturally occurring disease in HIV-infected human populations. 
 Goals of the present retrospective study included precise quantitation and 
characterization of inflammatory infiltrates within hearts of SIV-infected rhesus monkeys 
(Macaca mulatta) to allow objective comparison of inflammation severity between cases, 
and to allow correlations to be drawn between inflammation severity and the presence 
and number of intramyocardial virus-infected cells, as well as the size and distributional 
properties of local professional antigen presenting cell populations which could be 
expected to play a role in sensitization of the adaptive immune system to native or 
exogenous antigens within the myocardium. Two systems of quantitation were used in 
order to cross-check results, and to evaluate infiltrates not only in terms of cell numbers, 
as determined by quantitative image analysis, but also in terms of cell distribution, as 
determined by a rule-based grading schema.  
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Materials and Methods 
Animals, Case Inclusion Criteria, and Tissues.  Paraffin-embedded cardiac tissues 
from 26 rhesus monkeys (Macaca mulatta) were evaluated. Hearts from SIV-infected 
animals were selected from the pathology archives of the New England Primate Research 
Center. Hematoxylin and eosin (H&E)-stained sections were assessed to determine the 
presence or absence of lymphocytic inflammatory infiltrates, with infiltrates being 
defined as intramyocardial focal clusters comprised of 5 or more cells morphologically 
consistent with lymphocytes. Fourteen sequential cases with such infiltrates and the first 
7 cases without infiltrates were selected for further study. Hearts containing concurrent 
neutrophilic infiltrates or bacterial colonies were omitted from consideration. Cardiac 
tissues from 5 healthy, SIV-negative rhesus monkeys with no gross or histologic 
evidence of cardiac or other significant pathology were used as controls. All SIV-positive 
animals had been infected with either SIVmac251 or SIVmac239 and had been included 
in a variety of vaccine and pathogenesis studies. Post-inoculation time to euthanasia and 
necropsy ranged from 81 to 1502 days. Prior to euthanasia, all animals were housed at the 
New England Primate Research Center (NEPRC) in accordance with standards of the 
Association and Accreditation of Laboratory Animal Care and the Harvard Medical 
School Animal Care and Use Committee. All animals received complete necropsies upon 
euthanasia. 
 
Immunohistochemistry.  Formalin-fixed, paraffin-embedded tissues were sectioned at 
5μm for routine, single-label immunohistochemistry following an ABC immunostaining 
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technique as previously described [187]. Cell populations were characterized using 
antibodies specific for CD3 (rabbit polyclonal, A 0452, DakoCytomation, Carpinteria, 
CA), CD4 (clone 1F6, VP-C318, Vector Laboratories, Burlingame, CA), CD8 (clone 
1A5, VP-C325, Vector), CD68 (clone KP1, M 0814, DakoCytomation), DC-SIGN 
(polyclonal, gift of R. Doms, University of Pennsylvania, Philadelphia, PA, and clone 
120612, DZX02, R & D Systems, Minneapolis, MN), HAM 56 (clone HAM56, M0632, 
DakoCytomation), cleaved caspase 3 (polyclonal, Cell Signaling Technology, Beverly, 
MA), and Ki67 (clone MIB-1, M 7240, DakoCytomation). Intramyocardial virus was 
evaluated using antibodies against SIV nef protein (clone KK75, donor Dr. K. Kent and 
Ms C. Arnold, obtained from the NIBSC Centralised Facility for AIDS Reagents 
supported by EU Programme EVA contract (BMH4 97/2515) and the UK Medical 
Research Council), rhesus cytomegalovirus IE1 protein (polyclonal, provided by Dr. 
Peter Barry, UC Davis), and adenovirus (clone 20/11, MAB8052, Chemicon 
International, Temecula, CA). Formalin-fixed, paraffin-embedded (FFPE) splenic tissue 
from a rhesus monkey experimentally infected with SIV at the NEPRC served as positive 
control for immunohistochemical analysis of hearts for SIV nef protein. Formalin-fixed, 
paraffin-embedded jejunal tissue from an SIV infected rhesus monkey which developed 
severe adenoviral enteritis prior to euthanasia at the NEPRC served as positive control for 
adenoviral antigen. Formalin-fixed, paraffin-embedded tissue from the urinary bladder of 
an experimentally immunosuppressed cynomolgus monkey which spontaneously 
developed disseminated cytomegalovirus infection in an organ transplantation study at 
the NEPRC served as positive control for rhesus cytomegalovirus IE1 protein. Sections 
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were deparaffinized in xylene and  rehydrated through graded ethanols, followed by 
blocking of endogenous peroxidase by incubation in 3% H2O2 in phosphate buffered 
saline. Antigen retrieval in most cases consisted of microwaving in citrate buffer 
(Vector). Antigen retrieval for CD4 consisted of microwaving in EDTA buffer (Lab 
Vision, Fremont, CA), for adenovirus consisted of 5 minutes digestion with proteinase K 
(DakoCytomation), for CD8 consisted of 20 minutes pressure cooker treatment in Trilogy 
solution (Cell Marque, Hot Springs, AK), and for the DC-SIGN monoclonal consisted of 
microwaving in Tris HCl buffer (Lab Vision). Sections were incubated with primary 
antibody followed by an avidin-biotin block (Vector) to block endogenous biotin, and 
sequential incubation with biotinylated secondary antibody and horseradish peroxidase-
conjugated avidin (ABC Standard or ABC Elite, Vector), or the EnVision polymer 
system (DakoCytomation) applied according to manufacturer’s instructions. Antigen-
antibody complex formation was detected by use of 3,3’diaminobenzidine (DAB) 
chromogen (DakoCytomation) and tissues were counterstained with Mayer’s 
hematoxylin. Irrelevant primary antibodies were used in place of the test antibody as 
negative controls in all immunohistochemical studies.  
 
Grouping and Scoring.  Hearts from the 21 SIV+ cases were grouped into 3 cohorts of 7 
animals each based on application of the Dallas criteria to H&E stained sections from 
paraffin blocks containing left ventricular tissue [188]. Hearts assigned to the active 
myocarditis group had lymphocytic inflammatory infiltrates directly associated with 
regions of cardiomyocyte degeneration or necrosis, hearts assigned to the borderline 
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myocarditis group had lymphocytic infiltrates without associated cardiomyocyte 
degeneration or necrosis, and hearts assigned to the SIV normal group lacked 
inflammatory infiltrates and had no other histologic evidence of myocardial pathology. 
For each SIV-infected and control animal, sections of left ventricle were scored for 
necrosis on 2 non-serial H&E stained sections, and for immunohistochemical CD3 and 
CD68 signal according to specified distributional and quantitative parameters (Table 1). 
In brief, for each animal a single section of left ventricular tissue was scored for focal T 
cell infiltration, perivascular T cell infiltration, diffuse T cell infiltration, infiltrate-
associated macrophage involvement, and myofiber degeneration/necrosis, as defined. 
CD3 and CD68 scoring was limited to intramyocardial signal. Two composite scores 
were derived from the individual components: a total T cell infiltration score, generated 
as the sum of the 3 individual CD3 distributional scores, and a cumulative inflammation 
score, generated as the sum of the total T cell infiltration score, the necrosis score, and 
the infiltrate-associated macrophage score. Cytomegalovirus (CMV) involvement as 
detected by immunohistochemistry was scored semi-quantitatively on a 0-3 scale, with 0 
representing no positive signal, and 3 representing frequent signal.  
 
Quantitative Image Analysis.  For each SIV-infected and control animal, sections 
immunohistochemically labeled for SIV nef protein, CD3, CD68, and DC-SIGN as 
described were individually examined by use of an Olympus Vanox-S AHBS microscope 
interfaced with a Leica personal computer equipped with Leica QWin image analysis 
software (Leica Imaging Systems Ltd., Cambridge, England), via a DEI 750 charge-
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coupled device camera (Optronics, Goleta, CA). In brief, for a single section of left 
ventricular tissue from each animal, images of 20-30 random fields were captured at 200x 
magnification. The total number of DAB stained cells per field was quantitated based on 
the number of flagged foci of discrete signal occupying a minimum number of 
contiguous pixels. The number of positive cells per mm2 was calculated based on the 
known area of each field and total number of positive cells in the overall examined area. 
 
In Situ Hybridization.  In situ hybridization for SIV RNA in cardiac tissue was 
performed as previously described [189]. Briefly, tissue sections were deparaffinized and 
rehydrated in xylene and graded ethanols. Endogenous alkaline phosphatase activity was 
blocked in 5 mM levamisole (Sigma Chemical Co., St. Louis, MO). Sections were 
hydrolyzed in 0.2N HCl (Sigma), digested with proteinase K (Roche Diagnostics Corp., 
Indianapolis, IN), acetylated in acetic anhydride (Sigma), and hybridized overnight at 
50°C with digoxigenin-labeled antisense riboprobe that spans the entire genome of the 
SIVsmmPGm5.3 molecular clone of SIVsmmFGb (Lofstrand Laboratories, Gaithersburg, 
MD). Bound probe was detected by immunohistochemistry using alkaline phosphatase-
conjugated sheep anti-digoxigenin F(ab) fragments (Roche) and the chromogen nitro blue 
tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP, Roche). Sections were 
counterstained with nuclear fast red (Vector). Splenic tissue from an SIV-positive rhesus  
monkey hybridized with antisense riboprobe served as positive control. Splenic tissue 
from an SIV-negative rhesus monkey hybridized with antisense riboprobe and from an 
SIV-positive rhesus monkey hybridized with sense riboprobe served as negative controls.  
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Confocal Microscopy.  Double-label immunofluorescence confocal microscopy was 
performed on paraffin sections. Briefly, sections were routinely deparaffinized, 
rehydrated, subjected to antigen retrieval as described for single-label 
immunohistochemistry, washed in 1x phosphate-buffered saline in doubly distilled water 
with 0.2% fish skin gelatin (PBS-FSG), and blocked with 10% normal goat serum diluted 
in PBS-FSG.  Monoclonal primary  antibodies (specific for SIV nef, HAM 56, DC-
SIGN) were incubated on sections overnight. Polyclonal primary antibodies (specific for 
CD3) were incubated on sections for 30 minutes. Anti-mouse IgG1 Alexa 488 and anti-
mouse IgG2a Alexa 568, anti-mouse IgM Alexa 568, or anti-rabbit IgG Alexa 568 
secondary antibodies (Molecular Probes, Inc., Eugene, OR) were incubated for 30 
minutes on sections as appropriate for the species and isotype of primary antibody. To-
Pro3 (Molecular Probes) was incubated on sections for 5 minutes then washed with PBS. 
Confocal microscopy was performed using a Leica TCS SP laser scanning microscope 
equipped with 3 lasers (Leica Microsystems, Exton, PA). Thirty-two individual optical 
slices were collected at 512 x 512 pixel resolution. The fluorescence of individual 
fluorochromes was captured separately in a sequential mode, after optimization to reduce 
bleed-through between channels (photomultiplier tubes) using Leica software. Adobe 
Photoshop Elements 3.0 (Adobe Photosystems, San Jose, CA) was used to assign correct 
colors to 3 channels collected: Alexa 488 (green), Alexa 568 (red), and To-Pro3 (blue). 
Colocalization of antigens was demonstrated by the addition of colors. 
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Serology.  Banked sera from 50 rhesus monkeys of various ages and from various 
housing circumstances at the New England Primate Research Center were evaluated for 
the presence of anti-coxsackieviral IgG to assess the prevalence of coxsackievirus 
exposure in the Center’s rhesus population. A commercial ELISA kit with broad 
coxsackievirus serotype specificity and manufacturer-provided control sera was used 
according to manufacturer’s instructions (Serion ELISA, QED Biosciences, San Diego, 
CA).  
 
Statistical Analysis.  Linear regression analysis and statistical comparisons between 
groups were performed with commercially available software (SigmaStat 3.1, Systat 
Software, Inc., Richmond, CA). Groups were compared using the t test or Mann-Whitney 
Rank Sum Test, as appropriate. Fisher’s exact test was used to evaluate categorical data 
between groups. Probability values of P < 0.05 were interpreted as significant. Statistical 
analysis of quantitative image analysis data was performed on pooled individual data 
points collected for each animal within the evaluated groups.   
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Results 
Correlation between grading schema-derived composite scores and image analysis-
based T cell quantification  
There were no significant differences in age, sex, viral inoculum, or number of days post-
infection among the groups. AIDS-defining lesions, including disseminated opportunistic 
infections, giant cell disease, and SIV encephalitis, were present in a majority of animals 
in all SIV-infected groups at necropsy. Prevalence of AIDS diagnosis did not differ 
significantly between groups, being found in 4 of 7 cases with active myocarditis, 6 of 7 
cases with borderline myocarditis, and 5 of 7 cases with histologically normal 
myocardium. Mononuclear inflammatory infiltrates within the myocardium (Figure 2.1, 
A) were quantified using both quantitative image analysis and a rule-based grading 
schema (Table 2.1). Lymphocytic infiltrates detected with CD3 immunohistochemistry 
were scored according to focal (Figure 2.1, B), perivascular (Figure 2.1, C), and diffuse 
(Figure 2.1, D) distributions. Summation of individual, grading schema-derived 
distributional T cell scores yielded a composite total T cell infiltration score for each 
heart.  A significant correlation (P < 0.001) existed between composite T cell infiltration 
scores and values for the number of CD3+ cells/mm2 generated by quantitative image 
analysis (Figure 2.2, A). Infiltrate-associated macrophage involvement and 
cardiomyocyte degeneration and necrosis (Figure 2.1, E-F) were separately scored and 
combined with the T cell infiltration score to yield a cumulative inflammation score 
which significantly correlated with the T cell infiltration score itself (P < 0.001) and with 
image analysis values for CD3+ cells/mm2 (P = 0.003, R = 0.566) (Figure 2.2, B). The 
 29
pattern of significant correlations for individual grading schema derived T cell 
distribution scores was identical to that identified for image analysis derived quantitation 
of CD3+ cells, and each individual distribution score correlated significantly with image 
analysis derived T cell quantitation itself (P < 0.025). Individual T cell distributional 
scores also correlated significantly with each other (P ≤ 0.005) with the exception of the 
focal and diffuse scores (P = 0.09). In linear regression analyses examining the 
relationship between T cell infiltration and other examined parameters, the significance 
or non-significance of correlations patterned identically regardless of which T cell 
quantitation method was used for all parameters except one. The highly significant 
correlation of composite T cell infiltration scores with image analysis derived values for 
the number of CD3+ cells per unit area indicates that grading schema derived scoring may 
confidently be used as an alternate method for quantitation of inflammatory infiltrates in 
contexts where image analysis is not readily available.   
 
Quantitation and characterization of inflammatory infiltrates by group 
The amount of T cell infiltration, infiltrate-associated macrophage involvement, and 
cumulative inflammation as defined under the grading schema was determined for each 
group and compared between groups. Statistically significant elevations in T cell 
infiltration score (P < 0.05), infiltrate-associated macrophage score (P < 0.02), and 
cumulative inflammation score (P ≤ 0.03) were present in hearts with active or borderline 
myocarditis relative to SIV normal hearts and uninfected controls (Figure 2.3). 
Differences in these parameters between hearts with active myocarditis and those with 
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borderline myocarditis were not significant, nor were differences in values between SIV 
normal hearts and uninfected controls. Infiltrate-associated macrophage scores between 
the active and borderline myocarditis groups approached but did not achieve statistical 
significance (P = 0.064). Values for T cell infiltration score, CD3+ cells/mm2, cumulative 
inflammation score, and infiltrate-associated macrophage score did not differ 
significantly between animals with and without AIDS-defining lesions (all P > 0.10). 
Immunohistochemical analysis for CD8 and CD4 antigens was performed to 
further characterize the identified CD3+ cell populations. A strong predominance of CD8+ 
cells was noted in almost all cases (Figure 2.4, A), though 2 hearts had roughly equal 
numbers of CD4+ and CD8+ round cells within inflammatory foci, without an obvious 
correspondence between the CD4+ population and the CD68+ population evaluated from 
a separate section of the same tissue. CD4 signal in general was rare and, when present, 
occurred predominantly in loose distribution in the subendocardial space in a pattern also 
identified for CD68 (not shown). A minority of hearts, however, had large numbers of 
CD4+ cells with a spindloid morphology distributed throughout the myocardial 
interstitium (Figure 2.4, B). Hearts with high levels of interstitial spindloid CD4+ cells 
were unique in also having especially high numbers of interstitial DC-SIGN+ cells. 
 
Relation of cardiomyocyte necrosis to macrophage and T cell involvement  
Cardiomyocyte degeneration and necrosis were variably present among SIV+ animals 
with lymphocytic infiltrates and served as the defining criterion for inclusion in the active 
myocarditis group. Areas of necrosis were characteristically small and localized to a 
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single cardiomyocyte or directly adjacent cardiomyocytes (Figure 2.1, F). Three of 7 
hearts from the active myocarditis group also contained patchy regions of replacement 
fibrosis consistent with a process of chronic injury, a finding which was not present in 
hearts from any of the other 3 groups. A statistically significant correlation existed 
between the necrosis score and both the infiltrate-associated macrophage score (P < 
0.001, R = 0.666) and the cumulative inflammation score (P = 0.007, R = 0.517). No 
significant correlation was detected between necrosis score and either measure of T cell 
quantitation (T cell infiltration score P = 0.479, R = 0.145; CD3+ cells/mm2 P = 0.433, R 
= 0.161). 
The possibility of cardiomyocyte apoptosis as a significant contributor to 
myocardial pathology was investigated through immunohistochemical evaluation of the 
presence, frequency, and distribution of cleaved caspase 3. Cleaved caspase 3 signal was 
strong in sections of rhesus duodenum and tonsil used as positive controls, but very rare 
in hearts of all groups. Occasional cells morphologically consistent with leukocytes 
displayed strong positive signal within inflammatory foci or within the myocardial 
interstitium (not shown), but no positive signal in cells morphologically consistent with 
cardiomyocytes was identified.  
 
Intramyocardial SIV-infected cells and inflammation 
Intramyocardial SIV-infected cells were detected in 7 of the 21 hearts from SIV-infected 
animals by in situ hybridization using probes spanning the entire SIV genome. Infected 
cells were found in 3 of 7 hearts with active myocarditis, 1 of 7 hearts with borderline 
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myocarditis, and 3 of 7 hearts from the SIV normal group. SIV nef 
immunohistochemistry had a lower sensitivity than in situ hybridization, detecting only 5 
of 7 cases containing infected cells. Infected cells occurred with an interstitial distribution 
and had a compact, discrete, frequently spindloid morphology (Figure 2.4, C). Double-
label immunofluorescence confocal microscopy demonstrated consistent colocalization 
of SIV nef protein with HAM 56, indicating productive infection of macrophages (Figure 
2.4, D). A lack of colocalization of CD3 and SIV nef protein signal indicated a lack of 
productive infection of intramyocardial T cells (not shown). With one exception, 
numbers of infected cells in hearts where SIV antigen was detected were extremely low, 
ranging from <1 to 4 cells/mm2 by quantitative image analysis. A single heart within the 
SIV normal group contained substantially higher quantities of infected cells at 36 
cells/mm2, though with morphologic and distributional properties similar to those 
identified in other hearts. The quantity of SIV-infected cells per unit area was 
significantly higher among hearts from the SIV normal group than among hearts from 
either the active or borderline myocarditis groups (P < 0.04). No correlation was 
identified between the number of SIV-infected cells/mm2 and T cell infiltration score (P 
= 0.646, R = 0.106), CD3+ cells/mm2 (P = 0.742, R = 0.0821), cumulative inflammation 
score (P = 0.382, R = 0.201), necrosis score (P = 0.535, R = 0.144), infiltrate-associated 
macrophage score (P = 0.188, R = 0.299), or diffuse macrophage infiltration within the 
myocardial interstitium (CD68+ cells/mm2) as quantified by image analysis (P = 0.858, R 
= 0.0417).  
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Frequency of potentially contributory cardiotropic infections  
To evaluate the extent to which other opportunistic or general cardiotropic infections 
might contribute to induction of the myocardial inflammatory response in the hearts 
under study, specific screening was conducted for coxsackievirus, adenovirus, and 
cytomegalovirus, along with reviews of non-serial H&E stained sections for histologic 
evidence of opportunistic agents. Coxsackieviral IgG serology performed using 
manufacturer-provided controls was conducted on sera from 50 rhesus monkeys of 
various ages and housing circumstances at the New England Primate Research Center. 
Negative results were found in all cases, indicating that coxsackievirus infection is 
unlikely to play an important role among monkeys within the facility. 
Immunohistochemical screening for adenoviral antigen yielded strong, frequent signal on 
positive control tissues, but in all hearts revealed no positive signal.  Strong nuclear 
signal for rhesus cytomegalovirus IE1 protein was detected in cardiomyocytes of 6 of 21 
SIV+ animals by immunohistochemistry, with staining pattern and intensity matching that 
of positive control tissues. Cardiomyocyte CMV signal was identified in 2 hearts with 
active myocarditis and 4 hearts with borderline myocarditis, but not in any SIV normal or 
control hearts. Evidence of infection was not found in any cells other than 
cardiomyocytes. In all cases, infected cells occurred in low numbers and were not 
directly associated with inflammation or necrosis. The difference in CMV scores between 
hearts with active or borderline myocarditis as compared to SIV normal and uninfected 
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control hearts approached but did not reach statistical significance (P = 0.066).  Of 10 
animals with myocardial CMV-infected or SIV-infected cells, 3 contained both. Of these, 
2 were in the active myocarditis group, 1 was in the borderline myocarditis group. 
Cumulative inflammation scores for these 3 animals included 1 above the mean for all 
SIV+ animals as a group, 1 equal to the mean, and 1 below the mean. All of these hearts 
had very low numbers of myocardial SIV-infected cells. No correlation was detected 
between CMV score and T cell infiltration score (P = 0.853, R = 0.038), CD3+ cells/mm2 
(P = 0.640, R =0.00963), cumulative inflammation score (P = 0.520, R = 0.132), necrosis 
(P = 0.493, R = 0.141), DC-SIGN+ cells/mm2 (P = 0.226, R = 0.246), SIV+ cells/mm2 (P 
= 0.643, R = 0.107), or CD68+ cells/mm2 (P = 0.826, R = 0.0453).  
Multiple reviews of H&E stained sections by 2 individuals (JHY, KGM) revealed 
no histologic evidence of other protozoal, fungal, bacterial, or viral infections.  
 
DC-SIGN+ cells and T cell infiltration 
Distribution of DC-SIGN was evaluated as a dendritic cell marker which also labels some 
macrophage populations in both humans and macaques.[190-193] Tissue sections of left 
ventricle were immunohistochemically labeled for DC-SIGN with signal subsequently 
quantified by image analysis. DC-SIGN+ cells were identified in 23 of 26 hearts 
examined.  DC-SIGN+ cells occurred exclusively in the interstitium and perivascular 
connective tissue and were never found within inflammatory foci (Figure 2.4, E). The 
number of DC-SIGN+ cells was highly variable among samples, ranging from 0-77 
cells/mm2, and while variation in DC-SIGN+ cell numbers was found in all groups, 
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numbers of intramyocardial DC-SIGN+ cells were significantly increased in hearts of the 
SIV normal group relative to all other groups (P < 0.001) (Figure 2.5, A). DC-SIGN+ 
cells were also significantly increased in hearts from the active myocarditis group relative 
to the control group (P = 0.006); however, differences between DC-SIGN+ cell numbers 
in the active and borderline myocarditis groups, and between the borderline myocarditis 
and control groups were not significant (P = 0.113, and P = 0.220, respectively).  The 
possibility of intramyocardial proliferation of the DC-SIGN+ population being 
responsible for the dramatically higher levels of expression noted in some hearts was 
evaluated by assaying for the proliferating cell marker Ki67. Ki67 signal was detected 
among leukocytes within focal aggregates, but was not identified in more widely 
dispersed interstitial and perivascular cells consistent with the DC-SIGN+ populations 
identified.  
Hearts with high levels of T cell infiltration as quantitated by either method 
uniformly had low numbers of myocardial DC-SIGN+ cells, and among hearts from SIV-
infected animals there was a statistically significant inverse correlation between the 
number of DC-SIGN+ cells/mm2 and the T cell infiltration score (P = 0.027) (Figure 2.5, 
B).  A statistically significant direct correlation also was identified between the number 
of SIV-infected cells/mm2 and the number of DC-SIGN+ cells/mm2 (P = 0.038, R = 
0.456); however, the significance of this latter correlation depended critically on 
inclusion of the single SIV normal sample with very high numbers of myocardial SIV-
infected cells/mm2. Double-label immunofluorescence confocal microscopy 
demonstrated consistent absence of colocalization of DC-SIGN signal and SIV nef 
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protein within individual cells, indicating a lack of productive SIV infection in DC-
SIGN+ cells (Figure 2.4, F). 
Distinctness of DC-SIGN+ and CD68+ cell populations 
Distribution of CD68+ cells was evaluated to quantify macrophages, both within 
inflammatory foci and more diffusely throughout the myocardial interstitium. Quantity of 
CD68 signal was compared to image analysis derived quantification of DC-SIGN labeled 
sections of the same tissue in order to assess overall numbers and distribution of antigen 
presenting cells. CD68 immunohistochemistry revealed a population of cells with 
distribution and spindloid morphology similar to that identified for DC-SIGN, though 
CD68+ cells were also noted occurring within inflammatory foci (Figure 2.1, E). 
Myocardial CD68+ cell numbers were significantly increased in the active myocarditis 
group relative to uninfected controls (P = 0.034), and were significantly increased in the 
SIV normal group relative to the borderline myocarditis and uninfected control groups (P 
= 0.007 and P = 0.002, respectively). However, the frequency of CD68+ cells was lower 
than the frequency of DC-SIGN+ cells in sections of the same tissue, with DC-SIGN+ cell 
numbers being significantly higher in the SIV normal group (P < 0.001) (Figure 2.5, A, 
C). Linear regression analysis of the relationship of CD68+ cell frequency to DC-SIGN+ 
cell frequency demonstrated a statistically significant, but highly outlier dependent, 
correlation between the two (P = 0.020).  
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Discussion 
Quantification of infiltrates by image analysis and application of a rule-based grading 
schema provided two methods for objectively enumerating the extent and type of 
inflammation present in examined hearts, with the rule-based grading schema also 
allowing assessment of distributional patterns of infiltrates and derivation of composite 
scores incorporating multiple pathological features. The highly significant correlation of 
grading schema derived composite T cell infiltration scores with image analysis derived 
values for CD3+ cells/mm2 (P < 0.001) suggests that the inflammation grading schema 
may be used with confidence for quantitation of infiltrates in circumstances where 
computer-based image analysis is either not practical or not possible, such as in most 
clinical and diagnostic contexts. Interestingly, significant correlations from each of the 
individual distributional T cell scores did not differ from those of the image analysis 
derived quantitation of CD3+ cells per unit area, suggesting that the different 
distributional patterns identified within the tissues were not associated with different 
pathogenetic mechanisms or consequences, despite the fact that different hearts 
sometimes had pronounced differences in the distributional patterns of T cells present. 
The fact that cardiomyocyte necrosis scores lacked significant correlation with T 
cell infiltration, and that the active and borderline myocarditis groups consistently 
patterned together with regards to both the histologic characteristics of infiltrates and 
significant correlations with other examined parameters, suggests that these two groups 
represent slightly different manifestations of a single disease process. The fact that often 
only a small proportion of the infiltrates in hearts of the active myocarditis group were 
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directly associated with cardiomyocyte degeneration or necrosis further supports the 
existence of a continuum between these two groups, though the underlying cause of the 
cardiomyocyte injury and why it occurs in some cases and not others remains obscure.   
The potential role of macrophages in pathogenesis of cardiac disease in HIV 
infection has been raised as a point of interest in work by other groups [71]. In the present 
study, overall CD68+ cell numbers as quantitated throughout the myocardium by image 
analysis were not significantly different between hearts with active myocarditis and those 
which were histologically normal (Figure 2.5, C). CD68+ cell accumulation was most 
focally prominent in inflammatory cell infiltrates from hearts classified as having active 
myocarditis (Figure 2.3, B), but the fact that infiltrate-associated macrophage scores also 
correlated significantly with necrosis suggests the probability of a secondary clean-up 
response of macrophages to the presence of necrotic tissue in the context of active 
myocarditis as a possible explanation for this finding.  
 Productively SIV-infected cells were identified in 33% of the hearts from SIV+ 
animals; however, numbers of infected cells were generally very low. Productively 
infected cells were morphologically inconsistent with cardiomyocytes and consistently 
demonstrated colocalization of SIV nef protein with the macrophage marker HAM 56 
when examined by double-label immunofluorescence confocal microscopy, arguing 
against direct SIV infection of cardiomyocytes as a mechanism of myocyte injury.  The 
fact that the highest numbers of productively SIV-infected cells were found in hearts with 
histologically normal myocardium strongly argues against cardiomyocyte injury or 
secondary inflammatory reaction in response to the presence of SIV-infected leukocytes 
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within the myocardium. The finding of cardiomyocyte cytomegalovirus infection at 
relatively high frequency among the hearts with myocarditis, as has also been reported in 
several HIV-based studies [13, 18, 74], was suggestive of a possible role for CMV in the 
pathogenesis of this condition. Despite this, the lack of a significant correlation with 
either presence or quantity of inflammatory response, the fact that CMV-infected cells 
were never directly associated with regions of inflammation or necrosis, and the fact that 
most hearts with myocarditis did not contain evidence of CMV indicates that CMV 
infection is not sufficient to account for the full spectrum of cases examined. 
Furthermore, these facts taken together indicate that any role played by CMV would need 
to be indirect, possibly through induction of an autoimmune response, as has been 
documented in murine models of CMV infection [194-196]. 
 DC-SIGN+ cell numbers were dramatically increased in the SIV normal group 
compared to all other groups and showed an inverse correlation with quantity of T cell 
infiltration, suggesting an important immunoregulatory role for this population within the 
myocardium. The distribution of DC-SIGN+ cells diffusely throughout the interstitium 
and in perivascular locations suggests a surveillance function, and it may be that 
increased levels of surveillance by this cell population result in more rapid recognition 
and clearance of potential pathogens, thereby protecting against development of 
myocarditis. Conversely, the presence of significantly increased levels of local antigen 
presenting cells within the myocardium may increase the likelihood of inappropriate 
sensitization to native myocardial antigens under some circumstances, leading to 
increased likelihood of autoimmune responses. The exact identity of the DC-SIGN+ 
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population is not clear; however, the consistent lack of productive infection by SIV and 
the distinctness of this population from the CD68+ population based on quantitative 
inconsistencies between the two suggests that they are not macrophages and may well 
represent an immature dendritic cell population. Regardless of their exact identity, the 
nature of the correlations observed in these cohorts suggests that the recruitment of DC-
SIGN+ cells to the myocardium under conditions of SIV infection may play an important 
role in whether lymphocytic myocarditis develops in a given individual or not.  
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Table 2.1. Myocardial inflammation grading criteria 
_____________________________________________________________________________ 
Focal* T cell infiltration:  
0 =  no focus ≥5 CD3+ cells  
1 = 1-3 foci of ≥5<10 CD3+ cells  
2 = 4-6 foci of ≥5<10 CD3+ cells, OR 1-3 foci of ≥10<20 CD3+ cells  
3 = >6 foci of ≥5<10 CD3+ cells, OR >3 foci of ≥10<20 CD3+ cells, OR 1 or more foci of ≥20  
CD3+ cells 
 
Perivascular† T cell infiltration:  
0 = No 40x field containing ≥5 CD3+ cells associated with a single vessel 
1 = 1-2 40x fields each containing ≥5<10 CD3+ cells associated with a single vessel 
2 = ≥5<10 CD3+ cells associated with each of 3-5 vessels, OR 1 40x field containing ≥10<20  
CD3+ cells associated with a single vessel 
3 = ≥5<10 CD3+ cells associated with each of >5 vessels, OR ≥10<20 CD3+ cells associated  
with each of ≥2 vessels, OR  1 40x field containing ≥20 CD3+ cells associated with a single vessel 
 
Diffuse‡ T cell infiltration:  
0 = no 40x field with ≥8 CD3+ cells  
1 = 1-2 40x fields with ≥8<14 CD3+ cells  
2 = 3-6 40x fields with ≥8<14 CD3+ cells, OR 1-2 40x fields with ≥14<20 CD3+ cells  
3 = >6 40x fields with ≥8<14 CD3+ cells, OR 3 or more 40x fields with ≥14<20 CD3+ cells,  
OR 1 or more 40x fields with ≥20 CD3+ cells  
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Infiltrate-associated§ macrophages: 
0 = No CD68+ cells associated with any infiltrate 
1 = 1-5 CD68+ cells are present within a single infiltrate 
2 = 1-5 CD68+ cells are present within each of 2 or more infiltrates, OR >5 CD68+ cells are present  
within a single infiltrate 
3 = >5 CD68+ cells are present within each of 2 or more infiltrates 
 
Myofiber degeneration/necrosis:   
0 = none 
0.5 = 1 or more small foci cumulatively less than ¼ the size of a 40x field. 
1 = 1 or more small foci cumulatively less than ½ the size of a 40x field 
2 = 1 or more foci cumulatively greater than ½  the size of a 40x field but less than  
the size of a full 40x field 
3 = 1 of more foci cumulatively greater the size of a full 40x field 
_____________________________________________________________________________ 
 
*Focal T cell infiltrate: All CD3+ cells scored within a focus must be separated by no greater than 3 
lymphocyte diameters from another CD3+ cell within the focus. CD3+ cells within perivascular connective 
tissue are excluded from focal scoring. 
†Perivascular T cell infiltrate: All CD3+ cells scored as perivascular infiltrates must occur directly within 
perivascular connective tissue which does not overlap with any previously scored field. Infiltrates 
associated with multiple vessels (scores of 2 and above) may be in the same or different 40x fields. 
‡Diffuse T cell infiltrate: All CD3+ cells scored as diffuse infiltrates must be separated by greater than 3 
lymphocyte diameters from any focal or perivascular CD3+ infiltrate.   
§Infiltrate-associated macrophages: CD68+ cells scored as infiltrate-associated macrophages must be 
directly associated with a focal, diffuse, or perivascular lymphocytic infiltrate, as defined. 
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Figure 2.1  Myocardial infiltrates in SIV-associated myocarditis illustrating basic 
patterns evaluated under the grading schema. A: Interstitial mononuclear infiltrate with 
lymphocyte predominance and cardiomyocyte disruption (H&E) B: Predominantly focal 
aggregate of T cells (CD3 immunohistochemistry with Mayer’s hematoxylin) C:  
Perivascular T cell infiltration (CD3 immunohistochemistry with Mayer’s hematoxylin)  
D: Diffuse infiltration of T cells  without focus formation (CD3 immunohistochemistry 
with Mayer’s hematoxylin) E: Infiltrate-associated macrophage involvement (CD68  
immunohistochemistry with Mayer’s hematoxylin) F: Cardiomyocyte necrosis with 
associated inflammatory infiltrate (H&E) 
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Figure 2.1 
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Figure 2.2  Linear regressions illustrating correlations between grading schema derived T 
cell infiltration scores and image analysis based T cell quantitation, (A), and between 
grading schema derived T cell infiltration and cumulative inflammation scores, (B).  A: 
A statistically significant correlation was present between the numbers of CD3+ 
cells/mm2 as determined by image analysis and the grading schema derived composite T 
cell infiltration score, which incorporated individual scores for 3 different T cell 
distributional patterns (P < 0.001).  B: A statistically significant correlation was present 
between the image analysis derived quantitation of CD3+ cells/mm2 and the grading 
schema derived cumulative inflammation score, which incorporated the T cell infiltration 
score, the infiltrate-associated macrophage score, and the necrosis score (P = 0.003). 
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Figure 2.2 
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Figure 2.3  Distribution of T cell infiltration scores, infiltrate-associated macrophage 
scores, and cumulative inflammation scores across groups. A: T cell infiltration scores 
within the active and borderline myocarditis groups were significantly higher than within 
the SIV normal and control groups (P < 0.05). The difference in T cell infiltration scores 
between the active and borderline myocarditis groups and between the SIV normal and 
uninfected control groups was not significant. B: Infiltrate-associated macrophage scores 
within the active and borderline myocarditis groups were significantly higher than within 
the SIV normal or control groups (P < 0.02). The difference in infiltrate-associated 
macrophage scores between the active and borderline myocarditis groups and between 
the SIV normal and uninfected control groups was not significant.  C: Cumulative 
inflammation scores within the active and borderline myocarditis groups were 
significantly higher than within the SIV normal and uninfected control groups (P ≤ 0.03). 
The difference in cumulative inflammation scores between the active and borderline 
myocarditis groups and between the SIV normal and uninfected control groups was not 
significant. Boxes represent the 25th to 75th percentile of scores within each group. 
Central lines within boxes represent median values. Boxes without central lines have 
median values either equal to the box maximum (B: borderline group), or the box 
minimum (A: control group; B: active and control groups; C: control group). Active = 
active myocarditis group, borderline = borderline myocarditis group, SIV norm = SIV 
normal group, control = uninfected control group. 
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Figure 2.3 
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Figure 2.4  Immunophenotypic characterization and viral localization. A: Cells 
comprising cellular aggregates within the myocardium consisted predominantly of CD8+ 
lymphocytes. (CD8 immunohistochemistry with Mayer’s hematoxylin) B: An extensive 
interstitial spindloid CD4+ cell population was present in a small subset of SIV+ animals. 
This same subset of animals also had extremely high numbers of interstitial DC-SIGN+ 
cells. (CD4 immunohistochemistry with Mayer’s hematoxylin) C: Cells productively 
infected by SIV were characterized by compact, often spindloid morphology and 
interstitial distribution. (SIV nef immunohistochemistry with Mayer’s hematoxylin) D: 
Double-label immunofluorescence confocal microscopy for HAM 56 and SIV nef protein 
showed prominent cytoplasmic colocalization of nef protein signal with HAM 56 as 
indicated by addition of colors in the merged image (800x magnification). E: DC-SIGN+ 
cells had prominent spindloid morphology with a consistently interstitial and perivascular 
distribution. DC-SIGN+ cells were never identified within inflammatory foci. (DC-SIGN 
immunohistochemistry with Mayer’s hematoxylin) F. Double-label immunofluorescence 
confocal microscopy for DC-SIGN and SIV nef protein demonstrated a consistent lack of 
signal colocalization, indicating a lack of productive SIV infection in DC-SIGN+ cells 
(800x magnification). 
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Figure 2.4 
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Figure 2.5  Image analysis based quantitation of DC-SIGN+ and CD68+ cells. A:  DC-
SIGN+ cell numbers per unit area as measured by quantitative image analysis were 
significantly higher in the SIV normal group than in the active and borderline myocarditis 
groups or the uninfected control group  (P < 0.001). B: The grading schema derived T 
cell infiltration score was inversely correlated with the number of DC-SIGN+ cells/mm2 
(P = 0.027). C: CD68+ cell numbers per unit area as measured by quantitative image 
analysis were significantly higher in the SIV normal group than in the borderline 
myocarditis group or the uninfected control group (P = 0.007 and P = 0.002, 
respectively), and were higher in the active myocarditis group than in the uninfected 
control group (P = 0.034). Differences in CD68+ cell numbers between the active and 
borderline myocarditis groups and between the active myocarditis and SIV normal 
groups were not significant.  A, C: The number of DC-SIGN+ and CD68+ cells per unit 
area differed significantly within the SIV normal group (P < 0.001).  Boxes in (A) and 
(C) represent the 25th to 75th percentile of scores within each group. Central lines within 
boxes represent median values. Boxes without obvious central lines have median values 
visually indistinguishable from the box minimum (A, C: control group) or the box 
maximum (C: borderline group). Active = active myocarditis group, borderline = 
borderline myocarditis group, SIV norm = SIV normal group, control = uninfected 
control group. 
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Figure 2.5 
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CHAPTER III 
 
PHENOTYPIC VARIATION IN MYOCARDIAL MACROPHAGE POPULATIONS 
SUGGESTS A ROLE FOR MACROPHAGE ACTIVATION IN SIV-ASSOCIATED 
CARDIAC DISEASE 
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ABSTRACT 
Cardiac abnormalities are common in HIV-infected individuals, and have been especially 
well-documented as contributors to mortality in HIV-infected children. Underlying 
pathogenetic mechanisms responsible for myocardial disease in HIV-infection remain 
imperfectly understood.  SIV-infected rhesus monkeys develop a similar spectrum of 
cardiac lesions to those seen in HIV-infected people, providing an important model for 
pathogenesis studies. Retrospective analysis of cardiac tissue collected at necropsy from 
SIV-infected rhesus monkeys was performed to evaluate myocardial macrophage and 
dendritic cell populations as a function of previously quantitated lymphocytic 
inflammatory infiltrates and cardiomyocyte degeneration or necrosis. Variations in the 
size and phenotype of macrophage and dendritic cell populations were examined as 
possible contributors to the pathogenesis of SIV-associated inflammatory lesions. 
Macrophages labeling immunohistochemically for CD163 differed substantially from 
macrophages labeling for HAM56 in overall number, distribution across groups, 
involvement in inflammatory clusters, correlation with the DC-SIGN+ subpopulation of 
macrophages , and correlation with numbers of SIV-infected cells. CD163+ macrophages 
occurred in significantly higher numbers in uninflamed hearts from SIV-infected animals 
than in hearts from SIV-infected animals with myocarditis or uninfected controls (P< 
0.01). Numbers of CD163+ cells correlated positively with numbers of SIV-infected cells 
(P < 0.05) suggesting that the CD163+ population was associated with decreased 
inflammatory infiltration and reduced control of virus within the heart. As CD163 has 
been associated with non-classical macrophage activation and an anti-inflammatory 
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phenotype, these results suggest that a balance between classical and non-classical 
activation may affect levels of inflammatory infiltration and of myocardial virus burden. 
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Introduction 
 Currently, an estimated 38.6 million people world-wide are HIV-infected [60]. 
Cardiac abnormalities, including myocarditis and dilated cardiomyopathy, are common in 
HIV-infected individuals, and have been especially well-documented as contributors to 
mortality in HIV-infected children [28, 54]. Underlying pathogenetic mechanisms 
responsible for myocardial disease in HIV-infection remain imperfectly understood. HIV-
associated myocarditis has been a focus of interest given its high rate of occurrence, and 
the possibility that it may represent an etiologic precursor to cardiomyopathy [28, 63]. 
While recent reports suggest that use of highly active anti-retroviral therapy (HAART) 
may have decreased the frequency of HIV-associated myocardial disease, roughly 80% of 
those in need of anti-retroviral drugs globally still do not have access to them [59, 60]. 
Macrophages and dendritic cells constitute cell types which are widely distributed 
throughout peripheral tissues, serving as sentinels of the immune system and able to 
significantly modulate immune responses through cytokine production. While in some 
contexts the actions of these populations may result in the development of inflammatory 
responses, in other contexts their effects may be tolerogenic or overtly anti-inflammatory, 
with the differences between these scenarios attributable to differences in the phenotypic 
subsets of cells involved [167, 172, 173]. Immature dendritic cells have been associated 
with induction of peripheral tolerance, for instance, and non-classically activated 
macrophages have been associated with anti-inflammatory cytokine production profiles 
[172, 173]. As different subsets of macrophages and dendritic cells are capable of 
mediating profoundly different effects in tissue and previous work has demonstrated a 
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significant inverse correlation between numbers of myocardial DC-SIGN+ cells and local 
T cell infiltration in hearts from SIV-infected animals [158], it was hypothesized that 
phenotypic variations in antigen presenting cell populations within the myocardium could 
significantly affect induction of local inflammatory responses. 
 The simian immunodeficiency viruses (SIV) share a close phylogenetic 
relationship with HIV-1 and induce a fatal immunodeficiency syndrome in Asian 
macaques that provides an important model system for the study of HIV pathogenesis 
[176, 181],  Cardiac lesions and dysfunction in SIV-infection of rhesus monkeys 
(Macaca mulatta) closely match those described in HIV infection, suggesting a shared 
disease mechanism [158, 178].  Cardiomyopathy has been frequently documented among 
chronically SIV-infected rhesus monkeys, and while randomly distributed myocardial 
lymphocytic inflammatory infiltrates are frequently identified throughout the four 
chambers in these populations at necropsy, the inflammatory lesions tend to be mild with 
minimal associated necrosis [158, 178]. This suggests that factors other than direct 
myocardial damage by infiltrating inflammatory populations may be responsible for the 
development of cardiac dysfunction and raises the possibility that secreted soluble 
mediators may play a role in development of clinically significant cardiac pathology 
among HIV/SIV-infected individuals.  Macrophages and dendritic cells are important 
producers of inflammatory cytokines and chemokines, many of which have been 
demonstrated to have potent adverse effects on the heart [77, 113, 125, 134]. This is a 
point of particular relevance in HIV/SIV infection, a context intrinsically characterized 
by chronic immune activation and cytokine dysregulation [79, 81].  In the current study, 
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macrophage and dendritic cell populations are examined in archival myocardial tissue 
from SIV-infected and uninfected rhesus monkeys in which lymphocytic infiltration, 
viral involvement, and limited investigations into macrophage population sizes and 
phenotype have been previously reported [158].  Goals of the current study were to build 
on previous findings by characterizing the size, distribution, and phenotype of myocardial 
macrophage and dendritic cell populations, and to investigate a possible role for classical 
vs non-classical macrophage activation in SIV-associated myocardial inflammation. 
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Materials and Methods 
Tissue Groups.  Formalin-fixed paraffin-embedded (FFPE) cardiac tissues from 26 
rhesus monkeys (Macaca mulatta) from the pathology archives of the New England 
Primate Research Center were assessed in the present study. As previously described, 
twenty-one hearts were from SIV-infected animals, 5 were from healthy SIV-negative 
animals, and all had been  previously characterized for myocardial inflammation, 
cardiomyocyte necrosis, and myocardial viral involvement [158]. Case groupings have 
been previously described and were based on the presence or absence of lymphocytic 
infiltrates and cardiomyocyte degeneration or necrosis, in accordance with the Dallas 
criteria [158, 188]. In brief, H&E stained sections of left ventricle from SIV-positive 
animals were determined to have active myocarditis (lymphocytic infiltrates in direct 
association with cardiomyocyte degeneration or necrosis, referred to as the active group), 
borderline myocarditis (lymphocytic infiltrates with no associated cardiomyocyte 
degeneration or necrosis, referred to as the borderline group), or to be histologically 
unremarkable (referred to as the SIV normal group), with each group containing 7 hearts. 
Hearts from uninfected control animals (control group) contained no histologic lesions. A 
majority of animals in all SIV-infected groups had AIDS-defining conditions at necropsy. 
Detailed criteria used in case selection, characteristics of the animals used, and grouping 
of cases have been described previously [158]. No significant effects of gender, strain of 
viral inoculum, or number of days post infection were noted with respect to any features 
examined.  
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Immunohistochemistry.  Immunohistochemistry was performed on FFPE following an 
ABC immunostaining technique as previously described [187]. Tissues were assessed 
using antibodies specific for CD163 (clone 10D6, Lab Vision, Fremont CA), HAM 56 
(clone HAM56, DakoCytomation, Carpinteria CA), CD83 (clone 1H4b, Vector 
Laboratories, Burlingame CA), fascin (clone 55K-2, DakoCytomation), HLA-DP, DQ, 
DR (clone CR3/43, Dakocytomation), and HLA-DR (clone LN-3, Novocastra, Newcastle 
upon Tyne, United Kingdom). Sections were deparaffinized and rehydrated, followed by 
incubation in 3% H2O2 in phosphate buffered saline (PBS). Antigen retrieval consisted of 
microwaving in sodium citrate buffer (Vector) or Tris HCl buffer (Lab Vision). Sections 
were incubated with primary antibody followed by an avidin-biotin block (Vector), and 
sequential incubation with biotinylated secondary antibody and horseradish peroxidase-
conjugated avidin (ABC Standard or ABC Elite, Vector). Antigen-antibody complex 
formation was detected by use of 3,3’diaminobenzidine (DAB) chromogen 
(DakoCytomation).  Irrelevant, isotype-matched primary antibodies were used in place of 
the test antibody as negative controls in all immunohistochemical studies. 
 
Image Analysis and Scoring.  Sections immunohistochemically labeled for CD163, 
HAM56, and CD83 were examined with an Olympus Vanox-S AHBS microscope 
interfaced with a Leica personal computer equipped with Leica QWin image analysis 
software (Leica Imaging Systems Ltd., Cambridge England), via a DEI 750 charge-
coupled device camera (Optronics, Goleta, CA) [197]. In brief, for a single section of left 
ventricular tissue from each animal, images of 20-30 random fields of myocardium were 
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captured at 200x magnification. The total number of DAB stained cells per field was 
quantitated based on the number of flagged foci of discrete signal occupying a minimum 
number of contiguous pixels. The number of positive cells per mm2 was calculated based 
on the known area of each field and total number of positive cells in the overall examined 
area.  
Sections immunohistochemically labeled for HLA-DP, DQ, DR (hereafter 
referred to as “MHC class II”) and fascin were scored semiquantitatively on a 0-3 scale, 
with scores being applied blinded to group categorization of the samples. Separate scores 
were assigned for endothelial signal and for non-endothelial signal such that endothelial 
signal scores took into account only signal lining the myocardial intersitium in a pattern 
morphologically consistent with endothelium and non-endothelial signal scores took into 
account only clustered aggregations of signal not histomorphologically consistent with 
endothelium. In scoring, 0 represented no positive signal; 1 represented infrequent to rare 
signal; 2 represented moderate signal; and 3 represented extensive signal. Methods used 
for quantitation of necrosis through application of a rule-based grading schema have been 
previously described [158]. In brief, two non-serial H&E stained sections of left ventricle 
from each animal were scored on a 0-3 scale based on the cumulative area of necrosis in 
the two examined sections. Non-zero necrosis scores occurred exclusively in the active 
myocarditis group in keeping with the Dallas criteria-based definition of active vs 
borderline myocarditis. 
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Confocal Microscopy.  Confocal microscopy was performed on FFPE sections using 
primary antibodies specific for  CD163, HAM56, and HLA-DR, as described for single-
label immunohistochemistry, as well as anti-DC-SIGN (clone DCN46, BD Pharmingen, 
San Diego CA), anti-CD3 (rabbit polyclonal, DakoCytomation), anti-SIV nef (clone 
KK75, donor Dr. K. Kent and Ms C. Arnold, obtained from the NIBSC Centralized 
Facility for AIDS Reagents supported by EU Programme EVA contract (BMH4 97/2515) 
and the UK Medical Research Council), and anti-HIV-1 p24/SIV p27 (clone 183-H12-
5C, obtained through the NIH AIDS Research and Reference Reagent Program, Division 
of AIDS, NIAID, NIH: from Dr. Bruce Chesebro and Kathy Wehrly) [198-200]. Briefly, 
sections were deparaffinized, rehydrated, and subjected to antigen retrieval as for 
immunohistochemistry, washed in 1x PBS in ultrafiltered water with 0.2% fish skin 
gelatin (Sigma Aldrich, St. Louis MO) and 0.1% Triton X-100 (Sigma) (PBS-FSG-
Triton) and blocked with 10% normal goat serum diluted in PBS-FSG-Triton.  
Monoclonal primary antibodies were incubated on sections overnight. Polyclonal primary 
antibody was incubated on sections for 30 minutes. Irrelevant, isotype-matched primary 
antibodies or rabbit immunoglobulin fraction from healthy non-immunized rabbits 
(DakoCytomation) were used as irrelevant negative controls for each primary test 
antibody. Fluorochrome conjugated secondary antibodies (Molecular Probes, Eugene 
OR) were incubated on sections for 30 minutes. To-Pro3 (Molecular Probes) was 
incubated on sections for 5 minutes. Confocal microscopy was performed using a Leica 
TCS SP laser scanning microscope equipped with 3 lasers (Leica Microsystems, Exton 
PA). Colocalization of antigens was demonstrated by the addition of colors. Single- and 
 63
double-color positive controls were run in addition to irrelevant negative controls with 
each confocal experiment.  
As only 5 out of 21 hearts from SIV-infected animal had infected cells evident in 
the myocardium by nef immunohistochemistry and 3 of these 5 had infected cells 
occurring only in extremely low numbers, double-label experiments involving the 
antibodies SIV nef and SIV p27 were conducted using tissue from the 3 cases in which 
the largest number of SIV-infected cells had been documented by quantitative image 
analysis in previous work [158]. All specifically-labeled cells in all examined tissue 
sections were evaluated to ensure consistency of double-labeling patterns.  
 
Statistical Analysis.  Significance of differences between groups was determined using 
Kruskall-Wallis One Way ANOVA on Ranks with post-hoc pairwise comparison by 
Dunn’s test. Significance of distinctions between single paired evaluation categories was 
determined using the t-test or Mann-Whitney Rank Sum test as appropriate. Linear 
regressions were conducted to determine significance of correlations between CD163+, 
HAM56+, and CD83+ population sizes as well as endothelial and non-endothelial signal 
scores for MHC Class II and fascin (quantitation and scoring described above). 
Population quantitations and signal scores determined were further analyzed by linear 
regression with previously determined core parameters reflecting lymphocyte infiltration 
(CD3+ cells/mm2), numbers of virally infected cells (SIV nef+ cells/mm2), preliminary 
macrophage markers (DC-SIGN+ cells/mm2, CD68+ cells/mm2), and necrosis 
scores.[158] (SigmaStat 3.1, Systat Software, Richmond CA). Probability values of P < 
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0.05 were interpreted as significant. Statistical analysis of quantitative image analysis 
data was performed on pooled individual data points for each animal within evaluated 
groups.   
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Results 
Macrophage phenotype and population size varies significantly across groups 
Macrophages were enumerated and characterized using quantitative image analysis of 
sections immunohistochemically labeled for the macrophage-specific antigens CD163 
and HAM56. CD163 is a receptor which mediates endocytosis of hemoglobin-
haptoglobin complexes and has been associated with anti-inflammatory effects 
proceeding via multiple mechanisms [201, 202]. HAM56 is an as yet uncharacterized 
antigen which labels a large subset of cells of the monocyte-macrophage lineage and is 
frequently used to define tissue macrophage populations [203, 204]. Numbers of cells 
positive for each antigen were compared across the four groups: SIV active myocarditis, 
SIV borderline myocarditis, SIV normal, and uninfected controls. The number of CD163+ 
cells/mm2 varied dramatically across groups, with the highest numbers of  positive cells 
found in the hearts of SIV+ animals with histologically normal myocardium (P < 0.01), 
(Figure 3.1, A). Cells labeled for CD163 by immunohistochemistry occurred 
predominantly as individuated cells within the myocardial interstitium and perivascular 
tissue (Figure 3.2, A). While significantly higher numbers of CD163+ cells were found in 
the active group than the borderline and control groups (P < 0.01), the median number of 
CD163+ cells/mm2 in the active group (2.4 cells/mm2) was 40 times lower than that of the 
SIV normal group (96.4 cells/mm2), and maximal values in the active group (67 
cells/mm2) were less than half those of the SIV normal group (142 cells/mm2), (Figure 
3.1, A). Numbers of CD163+ cells were disproportionately increased in the active 
myocarditis group relative to the borderline group, but median values for numbers of 
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CD163+ cells/ mm2 between the active and borderline groups were essentially identical 
(2.4 positive cells/mm2 vs 3.2 positive cells/mm2, respectively). The significant 
difference between these two groups arose due to high CD163+ cell numbers in a 
minority of active myocarditis hearts that had especially low levels of T cell infiltration 
based on image analysis for CD3+ cells, suggesting a strong propensity for higher 
numbers of CD163+ cells to be associated with lower levels of lymphocytic infiltration, 
irrespective of the presence or absence of necrosis. 
Numbers of myocardial HAM56+ cells/mm2 showed less variability across groups 
than numbers of CD163+ cells, but were significantly higher in the active group than in 
any other group (P < 0.05) (Figure 3.1, B). Similar to CD163+ cells, HAM56+ cells 
occurred widely distributed within the myocardial interstitium and perivascular tissue 
(Figure 3.2, B-C). Numbers of myocardial CD163+ cells/mm2 differed significantly from 
numbers of HAM56+ cell/mm2 in evaluated hearts overall (P < 0.001), with significant 
differences in expression frequency of the two markers in the active myocarditis group (P 
< 0.01), the borderline myocarditis group (P < 0.01), and the uninfected control group (P 
< 0.01).  
 
Differences in distribution and correlations of CD163+ and HAM56+ cells 
Numbers of SIV infected cells cells/mm2 as previously determined by quantitation of 
cells labeling positive for SIV nef protein [158], correlated significantly with numbers of 
CD163+ cells/mm2 (P < 0.05, R = 0.465), but not with numbers of HAM56+ cells/mm2 (P 
= 0.833, R = 0.049). Neither CD163+ cell numbers nor HAM56+ cell numbers showed 
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significant correlations with previously quantitated numbers of CD3+ cells/mm2 or 
necrosis scores. Therefore, CD163+ macrophage populations demonstrated a significant 
relationship with numbers of virally infected cells which HAM56+ macrophage 
populations lacked, but neither population had a detectable correlation with the extent of 
myocardial inflammation or necrosis.  
Numbers of cells positive for CD163 correlated significantly with numbers of 
cells positive for all other examined macrophage markers including cells positive for 
HAM56 (P < 0.01, R = 0.512), and cells positive for the previously quantitated markers 
DC-SIGN (P < 0.001, R = 0.715) and CD68 (P < 0.05, R = 0.489). Numbers of CD163+ 
cells correlated particularly strongly with numbers of DC-SIGN+ cells, a population 
which has been previously demonstrated to have a significant inverse correlation with 
myocardial T cell infiltration in hearts from SIV-infected animals [158]. Numbers of 
HAM56+ cells also demonstrated a significant correlation with numbers of DC-SIGN+ 
cells, but the correlation was much weaker than that shown by CD163+ cells (P = 0.041, 
R = 0.403). Numbers of HAM56+ cells did not correlate significantly with numbers of 
CD68+ cells (P = 0.07, R = 0.362). 
 While both CD163+ and HAM56+ macrophages occurred predominantly in a 
dispersed distribution within the myocardial interstitium and perivascular connective 
tissue (Figure 3.2, B), marked differences were noted in the involvement of the two 
populations in focal aggregates of inflammatory cells. HAM56 signal within clusters of 
inflammatory cells was frequently extensive and strong, with only sparse CD163 signal 
in serial sections of the same clusters (Figure 3.2, D-E). The different levels of 
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involvement of these populations in such cellular aggregates suggests that HAM56+ cells 
may play a role distinct from CD163+ cells in the myocardial inflammatory response in 
SIV-infection. 
 
All myocardial SIV-infected cells and all myocardial DC-SIGN+ cells are CD163+  
Double-label confocal microscopy showed the significant correlations between CD163+ 
population size and numbers of SIV-infected cells, DC-SIGN+ cells, and HAM56+ cells 
to be due at least in part to co-expression of the evaluated markers. Double-labeling for 
SIV nef antigen and CD163 showed SIV nef signal occurring exclusively in CD163+ 
cells, though these cells constituted a minority of the total CD163+ population (Figure 
3.3, A). Double-labeling studies for SIV p27 antigen and CD163 yielded findings 
identical to those determined for nef and CD163, confirming the restriction of SIV 
infection to CD163+ cells (results not shown). Double-labeling studies for CD163 and 
DC-SIGN demonstrated DC-SIGN signal also to be consistently localized to CD163+ 
cells, though CD163+/DC-SIGN- cells were common (Figure 3.3, B). Double-labeling for 
CD163 and HAM56 demonstrated moderate numbers of cells positive for both markers in 
some hearts (Figure 3.3, C).  CD163+/HAM56+ phenotypes, CD163+/HAM56- and 
CD163-/HAM56+ phenotypes were all identified; however, with distributional frequency 
varying markedly across individual cases. 
 
Endothelial MHC class II expression correlates inversely with DC-SIGN+ cell 
numbers 
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MHC class II expression was evaluated as a marker for macrophage and dendritic cell 
activation. Strong MHC class II expression was present diffusely in many inflammatory 
clusters (Figure 3.4, A). Expression scores differed significantly across groups (P < 0.01), 
with higher scores in the active group than among uninfected controls (P < 0.05).  
Double-labeling studies examining distribution of HLA-DR and CD3 antigens resolved 
the MHC class II signal onto a set of discretely labeled cells, interspersed among T cells 
(Figure 3.4, B).  
MHC class II expression scores correlated significantly with previously 
determined numbers of myocardial CD3+ cells (P < 0.05) and scores for necrosis (P < 
0.001, R = 0.654), and by confocal microscopy showed a pattern of distribution in 
inflammatory clusters similar to that noted for HAM56 by immunohistochemistry (Figure 
3.4, B and Figure 3.2, E).  
Strong MHC class II labeling of microvascular endothelium in hearts from 
uninfected control animals was also present. Expression was variably reduced in hearts 
from SIV-infected animals, with hearts from animals of the active group in most cases 
having levels of signal indistinguishable from controls (Figure 3.4, C), but a majority of 
hearts in the SIV normal group having profound reduction or elimination of endothelial 
MHC class II signal. Differences in endothelial MHC class II scores between groups 
were significant (P < 0.05), and there was a significant inverse correlation between 
endothelial MHC class II scores and DC-SIGN+ cell numbers (P < 0.01, R = -0.517), 
suggesting a role for this population in homeostasis of MHC class II expression by 
cardiac endothelium (Figure 3.5).  
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Distribution and correlations of the dendritic cell markers CD83 and fascin 
Myocardial dendritic cell populations were evaluated using the antigens CD83 and fascin. 
Signal for CD83, an adhesion molecule of the immunoglobulin superfamily and highly 
specific marker for mature and activated dendritic cells [205, 206], and non-endothelial 
signal for fascin, a 55kD actin bundling protein expressed at high levels in mature 
dendritic cells [207], were identified almost exclusively in hearts from the two 
myocarditis groups. CD83+ cells occurred in very low numbers, both individuated in the 
myocardial interstitium and in small aggregates within clusters of inflammatory cells 
(Figure 3.6, A). CD83+ cell numbers correlated strongly with levels of T cell infiltration 
(P < 0.001, R = 0.923), (Figure 3.6, B).  
Distribution of fascin signal differed from that of CD83, with signal occurring in 
both endothelial and inflammatory-cluster-associated non-endothelial patterns which 
were separately scored. The non-endothelial signal pattern was found exclusively within 
clusters of inflammatory cells and occurred predominantly in the active myocarditis 
group (Figure 3.6, C). Non-endothelial fascin scores differed significantly across groups 
(P < 0.05), with scores being significantly higher in the active group than in the SIV 
normal group (P < 0.05). Non-endothelial fascin scores did not correlate significantly 
with numbers of myocardial CD3+ T cells (P = 0.679), but did correlate strongly with 
necrosis scores (P < 0.001, R = 0.635). Neither non-endothelial fascin scores nor CD83+ 
cell numbers correlated significantly with any of the evaluated macrophage markers, or 
with numbers of SIV infected cells. Endothelial fascin scores unlike inflammatory-
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cluster-associated fascin scores did not differ significantly across groups. However, like 
the inflammatory-cluster-associated scores, endothelial fascin scores showed a significant 
positive correlation with necrosis scores (P < 0.05, R = 0.467) and did not demonstrate 
any other significant correlations.  
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Discussion 
In hearts examined in the current study, CD163+ macrophages, which have been 
associated with an anti-inflammatory phenotype, occurred in significantly higher 
numbers in uninflamed hearts from SIV-infected animals than in hearts from SIV-
infected animals with myocarditis or uninfected controls. In addition, numbers of 
CD163+ cells showed a significant positive correlation with cell-associated myocardial 
virus burden. CD163+ macrophages have been associated with decreased lymphocyte 
activation, with inhibition of lymphocyte proliferation through release of soluble CD163 
cleaved from the membrane, and with anti-inflammatory cytokine production profiles 
[173-175, 202, 208-214]. Given this, our findings suggest that soluble mediators 
generated by the CD163+ population may have served to minimize lymphocytic 
infiltration, but possibly at the cost of increased tolerance of local viral infection. 
While overall numbers of CD163+ cells in examined hearts did not correlate 
significantly with levels of T cell involvement, the DC-SIGN+ subpopulation of CD163+ 
cells has previously been shown to correlate inversely with T cell infiltration, suggesting 
distinct functional roles for particular macrophage phenotypes within the myocardium 
[158]. Further supporting a unique role for this subpopulation was the finding of a 
significant inverse correlation between numbers of DC-SIGN+ cells and quantity of 
endothelial MHC class II signal, suggesting that secreted mediators produced by this 
population may modulate endothelial MHC class II expression.  
HAM56+ macrophages, in contrast, appeared in the highest numbers in hearts of 
animals with active myocarditis and occurred in disproportionately high numbers in the 
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inflammatory foci found exclusively in hearts of the two myocarditis groups. Hearts from 
the two myocarditis groups have been shown in previous work to contain significantly 
lower numbers of SIV-infected cells relative to hearts of the SIV normal group [158], 
suggesting that the inflammatory response present in the hearts of the myocarditis groups 
plays a role in containing local myocardial virus. However, many proinflammatory 
mediators, the secretion of which is characteristic of classically activated macrophages, 
have been shown in model systems to have significant adverse effects on the myocardium 
even in the absence of cardiomyocyte necrosis or apoptosis [77]. High levels of 
inflammatory cytokines have been demonstrated to be capable of inducing 
cardiomyopathy and heart failure in experimental models [134].These findings suggest 
that macrophages of the HAM56+/CD163- phenotype while associated with better control 
of local virus as part of a classical inflammatory response, may generate soluble 
mediators that could be associated with independent pathologic sequelae through direct 
effects on cardiomyocyte contractile function and/or hypertrophic gene expression 
patterns and through chemokine secretion attracting inflammatory cell populations into 
the tissue.  The fact that numbers of HAM56+ cells showed no significant correlation 
with measures of T cell infiltration or necrosis suggests that overall HAM56+ cell 
numbers within the myocardium are likely to be determined  by features other than 
simple responsiveness to inflammatory stimuli, though such responsiveness may be 
superimposed on effects of other factors determining steady state levels of resident 
macrophages within myocardial tissue.  
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SIV-infected cells within examined hearts were found to be uniformly CD163+, a 
finding consistent with a recent report demonstrating uniform expression of CD163 by 
SIV-infected cells in the brain, but contrasting with another report which found consistent 
downregulation of CD163 in HIV-infected macrophages in vitro [215, 216]. While 
productive SIV infection of DC-SIGN+ cell populations has been documented by other 
investigators in macaque intestinal tissue, previous work in cardiac tissue from this 
cohort has demonstrated that SIV-infected cells are consistently HAM56+ and DC-SIGN-, 
strongly suggesting that it is the CD163+/HAM56+ double-positive subpopulation which 
demonstrates productive SIV-infection, and that this population is distinct from the 
CD163+/DC-SIGN+ population [158, 217].  
In contrast to patterns identified for macrophage populations, distributional and 
correlative patterns of the activated dendritic cell markers CD83 and fascin suggest that 
they predominantly constituted reactive subsets responding to inflammation and necrosis 
present in hearts with myocarditis.  
In conclusion, the striking differences in frequency of specific macrophage 
phenotypes among groups, their different levels of involvement  directly within 
inflammatory lesions, and the prominent manifestation of a population which has been 
associated with an anti-inflammatory character in hearts lacking inflammation and with 
higher levels of myocardial virus, strongly suggests a role for macrophage phenotypic 
differences in susceptibility or protection from SIV-associated myocarditis, and raises the 
question whether myocardial macrophage populations may not also play an important 
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role in the development of cardiomyopathy through cytokine-mediated effects on the 
local tissue milieu. 
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Figure 3.1  Image analysis-based quantitation of CD163+ and HAM56+ cells by group. 
A: The number of CD163+ cells per unit area as measured by quantitative image analysis 
was significantly higher in the SIV normal and active myocarditis groups than in the 
borderline myocarditis or uninfected control groups (P < 0.01). Numbers of CD163+ cells 
per unit area were significantly higher in the SIV normal group than in the active 
myocarditis group (P < 0.01). The median number of CD163+ cells/mm2 in the SIV 
normal group (96 cells/mm2, central bar in box) was 40 times higher than the median 
number of CD163+ cells/mm2 in the active myocarditis group (2.4 cells/mm2, indicated 
by arrow). B: The number of HAM56+ cells per unit area was significantly higher in the 
active myocarditis group than in the borderline myocarditis group (P < 0.01), the SIV 
normal group (P < 0.05), or the uninfected controls group (P < 0.01). The number of 
HAM56+ cells per unit area in the SIV normal group was higher than in the uninfected 
control group (P < 0.01). Differences in numbers of HAM56+ cells per unit area between 
the borderline myocarditis and uninfected control groups were not significant. Boxes 
represent the 25th to 75th percentile of values within each group. Central lines within 
boxes represent median values. Boxes without evident central lines have median values 
visually indistinguishable from the box minimum (A: active myocarditis and control 
groups). 
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Figure 3.1 
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Figure 3.2  Immunophenotype, distribution, and morphology of macrophages within 
inflamed and uninflamed myocardium. A: CD163 cells had spindloid to occasionally 
stellate or rounded morphology and occurred predominantly as individuated cells within 
the myocardial interstitium and perivascular tissue. The frequency of positive cells varied  
across individual hearts from rare to profuse, with the highest numbers of positive cells 
occurring among hearts in the SIV normal group, in which histologic evidence of 
inflammation was absent. (CD163 immunohistochemistry with Mayer’s hematoxylin.) B: 
HAM56+ cells occurred widely distributed within the myocardial interstitium and 
perivascular connective tissue. The highest numbers of positive cells were found among 
hearts in the SIV-positive, active myocarditis group. (HAM56 immunohistochemistry 
with Mayer’s hematoxylin.) C: Morphology of HAM56+ cells ranged from elongate and 
spindled to compact and stellate. (HAM56 immunohistochemistry with Mayer’s 
hematoxylin.) D: CD163 signal was identified within myocardial clusters of 
inflammatory cells, but signal was often sparse and occurred in dramatically lower 
numbers than HAM56 signal present in serial sections of the same cluster, (compare to 
(E)). (CD163 immunohistochemistry with Mayer’s hematoxylin.) E: HAM56 signal 
within myocardial clusters of inflammatory cells was frequently extensive and strong, 
indicating the presence of a substantial macrophage population within such clusters 
(HAM56 immunohistochemistry with Mayer’s hematoxylin.)  
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Figure 3.2 
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Figure 3.3   
DC-SIGN+ cells and SIV-infected cells represent subsets of the CD163+ macrophage 
population. A: Double-label immunofluorescence confocal microscopy for CD163 and 
SIV nef protein showed productive infection of a subset of CD163+ cells. Nef+/CD163- 
cells were not identified.(CD163 and SIV nef immunofluorescence.) B: Double-label 
immunofluorescence confocal microscopy for CD163 and DC-SIGN showed delicate 
membranous colocalization of signal in a subset of spindloid interstitial cells. (CD163 
and DC-SIGN immunofluorescence.) C: Double-label immunofluorescence confocal 
microscopy for CD163 and HAM56 showed many cells positive for both CD163 and 
HAM56 signal. Signal varied from multifocal, noncolocalizing as shown, to diffusely 
colocalized (CD163 and HAM56 immunofluorescence).  
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Figure 3.3 
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Figure 3.4  Intramyocardial MHC class II expression A: Profuse MHC class II signal 
within clusters of inflammatory cells was often strong enough to significantly obscure 
nuclei of cells within the cluster. (HLA-DP, DQ, DR immunohistochemistry with 
Mayer’s hematoxylin.) B: Double-label immunofluorescence confocal microscopy 
consistently demonstrated failure of colocalization of MHC class II signal with CD3, 
instead labeling a separate population of often very numerous interspersed, discrete, CD3- 
round cells. (HLA-DR and CD3 immunofluorescence, 400x magnification.). Dispersed 
punctate to linear regions of intense 3-way colocalization not associated with the central 
inflammatory cell cluster are a product of erythrocyte autofluorescence in the myocardial 
microvasculature. C: MHC class II expression by cardiac microvascular endothelium in 
uninfected controls was profuse and strong. Expression was variably reduced in hearts 
from SIV-infected animals. Hearts from the active myocarditis group most closely 
resembled those of uninfected controls while dramatic reduction or elimination of signal 
was often found in hearts from the SIV normal group. (HLA-DP, DQ, DR 
immunohistochemistry with Mayer’s hematoxylin.)  
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Figure 3.4  
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Figure 3.5  A statistically significant inverse correlation was present between endothelial 
MHC class II scores and numbers of DC-SIGN+ cells/mm2 (P < 0.01, R = -0.517).  
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Figure 3.5 
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Figure 3.6  Morphology and distributional patterns of cells labeled with the dendritic cell 
markers CD83 and fascin and correlation of myocardial CD83+ cell numbers with T cell 
infiltration. A: CD83+ cells occurred in low numbers, being found both individuated in 
the myocardial interstitium and rarely in small aggregates within clusters of inflammatory 
cells, as shown. (CD83 immunohistochemistry with Mayer’s hematoxylin.) B: A highly 
significant correlation was present between the number of myocardial CD83+ cells/mm2 
and the number of myocardial CD3+ cells/mm2, (P < 0.001). C: Strong fascin signal was 
found within clusters of inflammatory cells, with signal typically arborizing through 
interstitial spaces between individual cells within the cluster. (fascin 
immunohistochemistry with Mayer’s hematoxylin.) 
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Figure 3.6 
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CHAPTER IV 
 
ANTIGENIC STIMULATION IN THE SIMIAN MODEL OF HIV INFECTION 
YIELDS DILATED CARDIOMYOPATHY THROUGH EFFECTS OF TNFα 
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ABSTRACT 
Objective: To investigate a role for endogenous myocardial cytokine production in 
development of HIV-associated cardiomyopathy. 
Design: Cardiomyopathy is a late-stage sequela of HIV infection. While pathogenesis of 
this condition in HIV infection is poorly defined, inflammatory cytokines are recognized 
for their detrimental effects on myocardial structure and function. HIV infection is 
characterized by chronic immune activation and inflammatory cytokine dysregulation. As 
the myocardium itself is a rich potential source of inflammatory cytokines, HIV-mediated 
cytokine dysregulation may be an important contributor to development of HIV 
cardiomyopathy. An antigenic stimulation protocol conducted in the SIV model of HIV 
infection was used to study effects of endogenous cytokine production on myocardial 
structure and function. 
Methods:  Twenty-six rhesus monkeys were assigned to treatment groups for a 35 day 
study. Animals were SIV-infected; SIV-infected and treated with killed Mycobacterium 
avium complex bacteria (MAC); SIV-infected, MAC-treated, and given the TNFα 
antagonist etanercept; or uninfected and MAC-treated. All animals were given weekly 
echocardiograms. Hearts were collected for further evaluation at euthanasia.  
Results: SIV-infected, MAC-treated animals developed significant systolic dysfunction 
(left ventricular ejection fraction (LVEF) decline of 19±2 %) and ventricular chamber 
dilatation (left ventricular end-diastolic diameter (LVEDD) increase of 26±6 %) not seen 
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in other groups. Concurrent treatment with etanercept prevented development of these 
changes, implicating a causative role for myocardial TNFα.  
Conclusions: SIV-infected animals develop exaggerated myocardial pathology on 
stimulation with the ubiquitous environmental agent MAC. These responses are TNFα-
dependent and may play a significant role in development of cardiomyopathy in HIV 
infection.  
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Introduction 
Ventricular dysfunction and dilated cardiomyopathy are well-documented 
sequelae of late-stage HIV infection [28, 37, 38, 53]. Factors influencing development of 
myocardial pathology in HIV infection are at present poorly defined. Hypothesized 
mechanisms have included cytokine-induced effects, tissue damage resulting from 
myocarditis, drug-induced cardiotoxicities, and effects of viral proteins [63, 76, 87, 89, 
91, 99, 100]. While current evidence suggests that highly active anti-retroviral therapy 
(HAART) has reduced the incidence of clinically significant cardiac disease among HIV-
infected people, such treatment is available to only a minority of those in need [59, 60]. 
In addition, HIV infection provides a defined venue for exploring the role of chronic 
immune activation and host inflammatory response in development and progression of 
myocardial injury, features which have relevance beyond the context of HIV-infection 
itself.  
 The myocardial tissue environment is a rich potential source of inflammatory 
cytokines, with both cardiomyocytes and local non-cardiomyocyte cell populations 
competent to produce a variety of inflammatory mediators, and heart tissue capable of 
generating as much or more TNFα per gram of tissue in response to endotoxin 
stimulation as liver or spleen [126, 151, 152, 155]. Non-myocyte populations comprise 
up to 70% of the total cellular constituency of the myocardium and consist of a mixed 
assemblage of cell types, including substantial populations of dendritic cells and 
macrophages [151, 156-159]. This represents a volatile setting in the context of HIV 
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infection, which is intrinsically characterized by chronic immune activation and 
inflammatory cytokine dysregulation [79, 81].  Inflammatory cytokine-induced 
myocardial dysfunction is a well-documented phenomenon in multiple experimental 
models, is a significant contributor to hemodynamic compromise in sepsis, and may play 
a contributory  role in development and progression of heart failure regardless of 
initiating etiology [77, 78, 113, 129, 130, 134]. Mechanisms of cytokine-induced 
contractile dysfunction are complex and multifactorial [77]. 
 Study of the pathogenesis of HIV-associated cardiomyopathy (HIVCM) in 
humans is limited by many factors. Identifying the earliest time points of development of 
myocardial pathology and placing them within the natural history of HIV infection is 
generally not possible; complex, variable, and potentially toxic medication regimens are 
routinely used; and there may be substantial variation in environment and lifestyle among 
patients.  The SIV model of HIV infection is well-established, has been extensively 
characterized, and provides a strong context for study of HIVCM in that dilated 
cardiomyopathy and histologic myocardial lesions similar to those documented in HIV 
infection are frequently seen in chronically SIV-infected rhesus monkeys, implying a 
shared pathogenesis [158, 178].  
 In the present study, an acute SIV infection model employing recurrent antigenic 
stimulation with whole, heat-killed Mycobacterium avium complex (MAC) bacteria was 
used to evaluate patterns of early SIV-associated myocardial injury. Pathogenesis studies 
focused on early time points post-infection allow evaluation of changes while viral loads 
are high, sufficient immune competence is retained to prevent opportunistic infections, 
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and effects of viral replication or viral determinants can be examined without 
complication by effects of differential disease progression. MAC bacteria are 
environmentally ubiquitous and disseminated MAC infections are among the most 
common opportunistic infections encountered in AIDS patients [218-220]. The MAC 
stimulation protocol applied represents an experimentally-induced augmentation of 
normal environmental antigenic stimulation, using an organism with a high degree of 
clinical relevance to late-stage HIV and SIV infection.  
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Materials and Methods 
Animals and Study Design.  Twenty-six male rhesus macaques (Macaca mulatta) aged 
2 to 4 years were housed at the New England Primate Research Center (NEPRC) in a 
biolevel 3 animal-containment facility in accordance with standards of the Association 
for Assessment and Accreditation of Laboratory Animal Care and Harvard Medical 
School’s Animal Care and Use Committee. Prior to initiation of experimental protocols, 
all animals tested negative for infection with simian retrovirus type D, SIV, simian T-
lymphotropic virus-1, and herpes B virus. Animals were divided into 4 cohorts for study 
over a 35 day period. Eighteen animals were subjected to infection with uncloned, 
pathogenic SIVmac251 (25ng p27 antigen in 1mL sterile phosphate buffered saline 
(PBS), IV) at day 0. Of these, 12 animals received 4 doses of heat-killed Mycobacterium 
avium complex bacteria (MAC, 107 CFU-equivalents in 1mL sterile PBS per 
administration, IV) with the first dose given at day 7, then repeated on days 12, 14, and 
21. Of the 12 SIV-infected, MAC-treated animals, 4 were treated with the TNFα 
antagonist etanercept (Enbrel™, Amgen, Thousand Oaks, CA) at 0.4mg/kg, IM every 
other day for the duration of the study. A control group of 8 SIV-uninfected animals was 
administered MAC treatments as described on the same schedule as the SIV-infected, 
MAC-treated animals. Blood drawn from all animals before virus inoculation at day 0, 
and weekly thereafter was evaluated for circulating cytokine and chemokine levels, 
peripheral T cell subset composition, and plasma viral load evaluation as appropriate. 
Echocardiograms were performed weekly, including prior to SIV inoculation on day 0, 
and prior to MAC treatments on days 7, 14, and 21. All echocardiographic studies were 
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conducted under ketamine sedation (10-15 mg/kg, IM). All SIV-infected animals and 4 of 
the 8 uninfected, MAC-treated animals were euthanized at the end of the study (30 mg/kg 
pentobarbital sodium, IV, followed by 2 mEq/kg potassium chloride, IV). Complete gross 
and microscopic post-mortem examinations were performed on all euthanized animals. 
Hearts were removed with myocardial tissue snap frozen and collected into formalin 
within 15 minutes of confirmation of death. 
 
Mycobacterium avium Complex (MAC) Inocula.  The MAC isolate used (no. 88415) 
was derived from a case of spontaneous disseminated mycobacterial disease in a rhesus 
monkey with simian AIDS, and retains the ability to generate disseminated infections in 
SIV-infected animals when not inactivated.[221]  Frozen stocks of the isolate were grown 
out in Middlebrook 7H9 broth at 37° C and 5% CO2 for 8 days, titered, diluted to 107 
CFU/mL in PBS, and killed by immersion in boiling water for 2 minutes. One mL of the 
heat-treated preparation was administered intravenously per animal per MAC treatment. 
The inoculum used produced no systemic signs of illness in treated animals as 
determined by clinical veterinary staff. 
 
Echocardiography.  M-mode and 2D echocardiograms were performed using a Hewlett 
Packard Image Point HX ultrasound machine and 5MHz transducer. Standard parasternal 
long and short axis views as well as standard two and four chamber apical views were 
obtained and recorded on VHS tape for later analysis using ImageView DCR (Nova 
Microsonics, Mahwah, NJ) and modified American Society of Echocardiography 
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volumetric analysis and regional and global wall motion scores. Heart rate was recorded 
using lead II of standard ECG. Analyses were conducted blinded to animal group 
allocations.  
 
ELISAs.  Commercial ELISA kits for soluble TNF receptors 1 and 2 (sTNFR1 and 
sTNFR2), monocyte chemoattractant protein-1 (MCP-1), and interleukin-18 (IL-18) 
(R&D Systems, Minneapolis, MN) were used on batched samples of previously frozen 
plasma according to manufacturers’ instructions. Evaluation of sTNFR2 levels in animals 
treated with etanercept was not possible due to cross-reactivity of the assay with 
etanercept itself. 
 
Western Blot.  Membrane fractions prepared using differential centrifugation of 
homogenates of snap frozen myocardial apex and semitendinosus muscle collected at 
necropsy were subjected to electrophoretic separation by SDS-PAGE, and 
electrotransferred onto PVDF membrane (Immobilon-PSQ, Millipore, Bedford, MA). 
Nonspecific protein binding was blocked and membranes were probed with primary 
antibody (anti-TNFα, AB-210-NA and clone 28410, R&D; anti-iNOS, clone 54, BD 
Biosciences, San Jose, CA). Blots were washed and incubated with secondary antibody 
conjugated to horseradish peroxidase (A5420, Sigma Aldrich, Milwaukee, WI; sc-2005, 
Santa Cruz Biotechnology, Santa Cruz, CA). Immunoreactive proteins were detected by 
chemiluminescence (PerkinElmer, Boston, MA) and exposed to X-ray film (Hyperfilm 
ECL, Amersham Pharmacia Biotech, Piscataway, NJ). Densitometric analysis of bands 
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was carried out using a Personal Densitometer SI and Image QuanNT Software 
(Molecular Dynamics, Sunnyvale, CA).  
 
Progression of SIV infection.  Plasma viral loads were determined by quantitative 
reverse transcription PCR, as described previously [222]. T cell subsets and total 
lymphocyte counts were monitored weekly throughout the study period.  
 
Histologic Examination and Immunohistochemistry.  Left and right ventricular free 
wall, interventricular septum, left and right atria, and aortic outflow tract were 
histologically examined for each animal. Immunostaining was performed as previously 
described, using an avidin-biotin complex method with diaminobenzidine (DAB, 
DakoCyomation, Carpineteria, CA) as chromogen [158]. Tissues were evaluated using 
antibodies specific for CD3 (A0452, DakoCytomation), cleaved caspase 3 (9661L, Cell 
Signaling Technology, Beverly, MA), SIV nef (clone KK75, donor Dr. K. Kent and Ms 
C. Arnold, from NIBSC Centre for AIDS Reagents supported by EU Programme EVA 
contract (QLKZ-CT-1999-00609) and the UK Medical Research Council),  HIVp24/SIV 
p27 (clone 183-H12-5C, obtained through NIH AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: from Dr. Bruce Chesebro and Kathy Wehrly), 
rhesus cytomegalovirus IE1 protein (polyclonal, provided by Dr. Peter Barry, UC Davis), 
and adenovirus (clone 20/11, Chemicon International, Temecula, CA) [198].  
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Tissue Scoring.  Myocardial tissue was scored in a blinded fashion for lymphocytic 
infiltration using a grading schema applied to sections immunohistochemically labeled 
for CD3, as previously described [158].  
 
Statistical Analysis.  Significance of differences between groups was determined using 
One Way ANOVA and Kruskall-Wallis ANOVA on Ranks as appropriate, with post-hoc 
pairwise comparison by Holm-Sidak or Dunn’s method, respectively. Linear regressions 
were conducted to determine significance of correlations. All analyses were conducted 
with commercially available software (SigmaStat 3.1, Systat Software, Richmond CA). 
Probability values of P < 0.05 were interpreted as significant.  
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Results 
Mycobacterial Antigenic Stimulation Yields Biventricular Dilatation and 
Myocardial Dysfunction in SIV-infected Rhesus Monkeys which is Preventable by 
TNFα Blockade 
Significant biventricular chamber dilatation developed among SIV-infected, MAC-
treated animals (SIV+MAC group) by day 35 as evidenced by increased right and left 
ventricular end-diastolic and end-systolic diameters relative to baseline (P < 0.001) 
(Table 4.1). Chamber diameters of MAC-treated, uninfected controls (MAC group) also 
showed significant changes relative to baseline (P < 0.05), but these were mild and 
consistent with dilatation only in the right ventricle (Table 4.1).  Significant changes in 
chamber diameter were absent in SIV-infected animals not treated with MAC (SIV 
group) (Table 4.1). 
Significant decreases in systolic function developed in SIV+MAC animals over 
the course of the study period as identified through declines in right and left ventricular 
fractional shortening and in left ventricular ejection fraction relative to baseline values (P 
< 0.05 right ventricular change;  P < 0.001 left ventricular changes) (Table 4.1; Fig. 4.1 
C, D). Such changes were absent in animals of the SIV group, and changes in the MAC 
group while significant, were mild and limited to declines in left ventricular fractional 
shortening (P < 0.05) (Table 4.1).  In keeping with the structural and functional changes 
which occurred in members of the SIV+MAC group, a mild but statistically significant (P 
< 0.05) increase in heart rate also developed in these animals which did not occur in other 
groups (Table 4.1). Strikingly, treatment of SIV-infected, MAC-treated animals with the 
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TNFα antagonist etanercept was completely protective against development of both 
chamber dilatation and systolic dysfunction (Table 4.1).  
Different kinetics characterized the observed alterations in ventricular chamber 
size and onset of systolic dysfunction (Fig. 4.1, A-B). Indicators of ventricular chamber 
size, such as left-ventricular end-diastolic diameter (LVEDD), showed an abrupt increase 
in the SIV+MAC group at the final examined time point (Fig. 4.1, A), while indicators of 
systolic dysfunction developed gradually, becoming prominent from day 21 onward (Fig. 
4.1, B).  
Significant differences in percent change LVEDD from baseline were present 
among the test groups over the study period (P < 0.001 overall, P < 0.01 at day 35) (Fig. 
4.1, A). Percent change in LVEDD relative to baseline at day 35 differed significantly 
between the SIV+MAC group and the uninfected MAC group (P < 0.001) (Fig. 4.1, E). 
Significant differences in percent change LVEF from baseline were also present among 
test groups (P < 0.001 overall, P < 0.001 at day 28) (Fig. 4.1, B). Percent change in LVEF 
relative to baseline at day 28 differed significantly between the SIV+MAC group and 
each of the other three groups (P < 0.001 between SIV+MAC and the SIV-infected, 
MAC-treated, etanercept-treated group, P < 0.001 between SIV+MAC and the SIV 
group, and P < 0.05 between SIV+MAC and the MAC group). Percent change in LVEF 
for the MAC group at day 28 also differed significantly from percent change LVEF for 
the SIV-infected, MAC-treated, etanercept-treated group (P < 0.05), a product of the 
combined mild decrease in LVEF for the MAC group and the mild increase in LVEF for 
the etanercept-treated group. 
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Mycobacterial Antigenic Stimulation Significantly Increases Myocardial TNFα 
Levels in SIV-Infected Animals, an Effect Prevented by Etanercept Treatment 
Levels of myocardial TNFα as evaluated by densitometric analysis of western blots were 
significantly higher in hearts from animals of the SIV+MAC group than in hearts from 
animals of the SIV group (P < 0.05) (Fig. 4.2, A).  Levels of TNFα were also 
significantly higher in cardiac muscle than in skeletal muscle for animals of the 
SIV+MAC group (P < 0.05), suggesting a tissue-specific effect of the mycobacterial 
antigenic stimulation rather than a generalized systemic increase in TNFα production 
(Fig. 4.2, B). In contrast, levels of myocardial TNFα in SIV-infected, MAC-treated, 
etanercept-treated animals remained low, approximating those in skeletal muscle (Fig. 
4.2, B).  
 
Plasma sTNFR2 and IL-18 Levels at Day 14 Correlate Significantly with Changes in 
Left Ventricular Chamber Diameter while Baseline Levels of IL-18 Correlate with 
Development of Systolic Dysfunction 
In SIV-infected groups, plasma levels of both sTNFR2 and IL-18 became significantly 
elevated (P < 0.001) relative to baseline by day 14, corresponding with the occurrence of 
peak viremia (Fig. 4.3 A, B). Percent change in LVEDD at day 35 correlated significantly 
with sTNFR2 levels at every time point from day 14 forward (day 14: P = 0.005, R = 
0.578; day 21: P = 0.006, R = 0.567; day 28: P = 0.028, R = 0.479; day 35: P = 0. 018, R 
= 0.499) such that higher levels of sTNFR2 were associated with greater left ventricular 
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chamber enlargement at the final measured time point (Fig. 4.3, C).  Elevations in plasma 
IL-18 at day 14 also correlated significantly with increased LVEDD at day 35 (P < 0.05, 
R = 0.407) such that higher levels were associated with greater left ventricular chamber 
enlargement at the final measured time point (Fig. 4.3, D). In contrast, baseline IL-18 
levels correlated negatively with development of systolic dysfunction as measured by 
percent change in LVEF at day 35 (P < 0.05, R = 0.445), such that higher levels of IL-18 
at day 0 were  associated with greater preservation of systolic function at the terminal 
time point (Fig. 4.3, E).  
Neither plasma sTNFR1 nor plasma MCP-1 showed significant correlations with 
echocardiographic parameters at any time point.  
 
Inducible Nitric Oxide Synthase (iNOS) Levels, Lymphocytic Infiltration, Plasma 
Viral Load, Myocardial SIV-infected Cell Burden, and Peripheral CD4 T Cell 
Counts Show No Significant Correlations with Measures of Ventricular Chamber 
Diameter or Systolic Function  
The cardiodepressant effects of nitric oxide serve as one of the central effector 
mechanisms by which inflammatory cytokines impact cardiac function [77]. Myocardial 
iNOS levels were higher in all SIV-infected groups relative to the uninfected MAC 
control group, and this difference was statistically significant between the MAC group 
and the SIV+MAC group (P < 0.05); however, myocardial iNOS levels did not differ 
significantly among SIV-infected groups (Fig. 4.4, A) and there were no significant 
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correlations between iNOS levels and any examined measure of either ventricular 
chamber diameter or systolic function. 
Histologically, mild inflammatory infiltrates were present in multiple hearts, 
though cardiomyocyte necrosis was not a prominent feature in any. Quantitation of 
lymphocytic infiltrates based on rule-based scoring of CD3-labeled tissue sections [158] 
demonstrated no significant differences between groups (P > 0.1) and no significant 
correlations with any measure of systolic function or ventricular chamber diameter.   
Myocardial infected cell burden, assessed by quantitation of positive signal in 
sections immunohistochemically labeled for SIV nef and SIV p27 gag proteins, 
demonstrated infected cells within hearts of 6 of the 18 SIV-infected animals. In each 
case, SIV-infected cells were rare (1-3 per animal), were exclusively interstitial in 
location, and were morphologically consistent with lymphocytes or macrophages (Fig. 
4.4, C). All hearts were negative for adenovirus and cytomegalovirus by 
immunohistochemistry. Numbers of myocardial SIV-infected cells did not correlate 
significantly with any measure of systolic dysfunction or ventricular dilatation.   
Plasma viral load in SIV-infected groups also did not correlate significantly with 
any measure of ventricular chamber diameter or systolic function. Viral loads within the 
SIV-infected, MAC-treated, etanercept-treated group, which developed no structural or 
functional pathology, were significantly higher (P < 0.05) than in the SIV+MAC group, 
which developed significant adverse structural and functional changes (Fig. 4.4, B). 
CD4 T cell counts differed significantly among groups overall (P < 0.001), as all 
three SIV-infected groups developed significant decreases relative to the uninfected 
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MAC group over the course of the study (P < 0.01). Counts among the SIV-infected 
groups did not significantly differ however, and there were no significant correlations 
between CD4 T cell counts and any evaluated echocardiographic parameter (Fig. 4.4, D).  
Immunohistochemical staining of tissue sections for cleaved caspase 3 as an early 
indicator of apoptosis revealed infrequent staining within inflammatory cell clusters, and 
strong appropriate staining on positive control sections of ileum, but no staining of 
cardiomyocytes in any section and no correlations with any echocardiographic parameter.  
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Discussion 
In the presented model, recurrent antigenic stimulation with heat-killed, 
opportunistic mycobacteria yielded significant myocardial contractile dysfunction and 
ventricular chamber dilatation in SIV-infected animals during acute infection which was 
not seen with SIV-infection alone and was mild to absent in uninfected animals treated 
with the same stimulation protocol. While the rapidity of induction of cardiac dysfunction 
in this model differs from that seen in natural disease, the findings suggest a fundamental 
hyperresponsivity of hearts from SIV-infected animals to antigenic stimulation. The 
cardiac changes induced by antigenic stimulation in this acute SIV-infection model 
reached magnitudes similar to those previously identified in studies of dilated 
cardiomyopathy in chronic SIV infection [178], while excluding many potential 
confounders which complicate interpretation in late stage infection. Concurrent 
etanercept treatment protected SIV-infected, MAC-treated animals from development of 
pathologic myocardial changes, suggesting a critical role for TNFα in induction of these 
changes. While it is not possible to control for variation in host immune response using 
small numbers of test subjects, these findings suggest that endogenous production of 
TNFα upon antigenic stimulation in the context of SIV infection is sufficient to induce 
significant cardiac dysfunction and implies exaggerated myocardial production of and/or 
responsiveness to TNFα by SIV-infected animals. In addition, the striking difference in 
myocardial TNFα levels between SIV-infected, MAC-treated animals which received 
etanercept and those which did not implies an important role for TNFα autoinduction in 
generation of the observed elevations in SIV-infected, MAC-treated animals [223]. This 
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finding suggests that even mild hyperresponsivity in the initial TNFα response might be 
rapidly enhanced through positive feedback loops.  
As further evidence of the importance of activation of the TNF system in 
evolution of the observed changes, plasma sTNFR2 levels from day 14 onward correlated 
significantly with extent of LVEDD change at day 35, predicting chamber dilatation with 
high sensitivity. IL-18 levels at day 14 also correlated positively with extent of LVEDD 
change, but as plasma IL-18 and sTNFR2 values correlated closely with one another, 
(day 14: P < 0.001) the relationship between IL-18 and LVEDD may have simply 
reflected a connection between myocardial remodeling and the overall systemic 
inflammatory response. Nevertheless, the finding that higher levels of both sTNFR2 and 
IL-18 at day 14 correlated with increased percent change LVEDD at day 35 suggests that 
the degree of activation of the inflammatory response around the period of peak viremia, 
during which viral replication is largely uncontrolled and early components of the innate 
immune response are activated, may directly contribute to the extent of subsequent 
structural change. This suggests that immune activation, well recognized as a major 
contributor to progression of SIV and HIV infection [139], may also play an important 
role in myocardial end organ damage.  In contrast, while elevated levels of  IL-18 have 
been associated with myocardial contractile dysfunction [113, 115, 116], lower levels of 
IL-18 at baseline were associated with more severe declines in LVEF at later time points, 
suggesting that pre-infection innate immune activation state may also play an important 
role in divergent post-infection myocardial effects.  
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 In the present model of HIVCM pathogenesis, no evidence was found for a role 
played by plasma viral load, myocardial infected cell burden, peripheral CD4 T cell 
count, myocardial lymphocytic infiltration, cardiomyocyte apoptosis, or cardiomyocyte 
necrosis. While iNOS has been implicated in the impairment of myocardial function in 
inflammatory contexts [77],  myocardial iNOS levels did not differ significantly among 
SIV-infected groups in this model. Likewise, while HIV gp120 protein has been 
demonstrated to be negatively inotropic in vitro[89] and high viral loads might therefore 
be expected to be associated with alterations of contractile function, no correlations were 
identified between plasma viral load and any examined measure of ventricular chamber 
diameter or systolic function.  
Prominent myocardial pathology developed over the 35 day study period in SIV-
infected, MAC-treated animals, but not in uninfected MAC-treated controls or animals 
which were SIV-infected alone. Treatment with the TNFα blocking agent etanercept 
proved fully protective from development of myocardial pathology, indicating that 
abnormal TNFα responses to the administered mycobacterial stimulus played a critical 
role in development of the observed changes. These findings suggest that aberrant 
inflammatory cytokine responsiveness to antigenic stimulation in the context of SIV or 
HIV infection may play an important role in the pathogenesis of cardiomyopathy. As 
myocardium-specific abnormalities in the cytokine response to antigenic stimulation 
appear central to the cardiac changes documented, defining the mechanism by which this 
occurs will be critical to understanding their ultimate causation. 
Table 4.1. Cardiac Functional and Structural Parameters  
           SIV+MAC      SIV                   Etanercept   MAC 
______________________________________________________________________________________________________ 
     Day 0  Change(%)  Day 0     Change(%)  Day 0     Change(%) Day 0      Change(%) 
LVEDD* (cm)   1.8±0.06     26±6‡ 1.9±0.04      1±3    1.6±0.04     4±6  1.9±0.06   -5±2§ 
LVESD* (cm)   1.1±0.07     41±6‡ 1.1±0.08      6±7  1.0±0.08     4±9  1.1±0.05      3±4 
LVEF† (%)    75±1     -17±4‡ 76±4      -1±4  74±3        5±7  79±2    -7±4 
LVFS (%)    37±2     -20±5‡ 40±4         0±10 34±4       23±28 42±1   -11±5§ 
RVEDD† (cm)   1.6±0.1     21±4‡ 1.0±0.04      -6±6  1.1±0.05       4±9  1.5±0.09      7±3§ 
RVESD† (cm)    1.0±0.05     45±10‡ 0.7±0.03     -10±7 0.7±0.06      19±12 1.0±0.05    14±6§ 
RVFS (%)    37±2    -30±11§ 29±3         17±15 36±5   -16±17  29±2    -11±6 
HR (bpm)    143±4     11±5§ 147±12     -12±12 145±16     13±17  168±7         -2±6 
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______________________________________________________________________________________________________  
SIV+MAC: SIV-infected animals treated with recurrent doses of heat-killed M. avium complex (MAC); SIV: SIV-infected 
animals not subjected to MAC treatments; Etanercept: SIV-infected, MAC-treated, etanercept-treated animals; MAC: 
uninfected, MAC-treated controls 
Day 0: Baseline value; Change(%): Percent change from baseline at day 35; All values given as mean ± standard error.  
LVEDD indicates left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular 
ejection fraction; LVFS, left ventricular fractional shortening; RVEDD, right ventricular end-diastolic diameter; RVESD, right 
ventricular end-systolic diameter; RVFS, right ventricular fractional shortening; HR, heart rate; bpm, beats per minute 
Difference between groups is significant: *P < 0.001, †P < 0.05.  
Percent change from baseline to day 35 is significant: ‡P < 0.001,   §P < 0.05 
Figure 4.1  Echocardiographic changes among study groups. (A) Animals in the 
SIV+MAC group developed abrupt, significant increases in left ventricular end-diastolic 
diameter (LVEDD) at the final examined time point which were absent in other treatment 
groups. Differences between groups were statistically significant (P < 0.001). (B) 
Animals in the SIV+MAC group developed progressive decreases in left ventricular 
ejection fraction (LVEF) which were minimal to absent in other treatment groups. 
Differences between groups were statistically significant (P < 0.001). (C) M-mode image 
from rhesus monkey with normal left ventricular function (LVEF, 80%). (D) M-mode 
image from rhesus monkey with markedly decreased left ventricular function (LVEF, 
45%). (E) Percent change in LVEDD at day 35 differed significantly across groups (P < 
0.01). Percent increase in LVEDD for the SIV+MAC group differed significantly (*) 
from baseline (P < 0.001) and from percent change LVEDD at day 35 for the uninfected 
MAC group (P < 0.001). (F) Percent change in LVEF at day 28 differed significantly 
across groups (P < 0.001). Percent decrease in LVEF at day 28 for the SIV+MAC group 
differed significantly (*) from baseline (P < 0.001), as well as from percent change LVEF 
in the SIV group (P < 0.001), the etanercept-treated group (P < 0.001), and for the MAC 
group (P < 0.05). Percent change LVEF for the MAC group at day 28 differed 
significantly (**) from percent change LVEF for the etanercept-treated group (P < 0.05). 
SIV+MAC: SIV-infected, M. avium complex (MAC)-treated group; SIV: SIV-infected 
animals not subjected to MAC treatments; SIV+MAC+Enbrel and Enbrel: SIV-infected, 
MAC-treated, etanercept-treated animals; MAC: uninfected, MAC-treated controls. 
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Figure 4.1 
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Figure 4.2  Local TNFα levels in myocardial and skeletal muscle tissue. (A) 
Myocardial TNFα levels were significantly higher in hearts from the SIV+MAC group 
(*) than in hearts from the SIV group (P < 0.05). (B) TNFα levels in cardiac muscle of 
animals from the SIV+MAC group (SIV+MAC H) were significantly higher (*) than in 
skeletal muscle from either the SIV+MAC group (SIV+MAC SM) (P < 0.05) or the SIV-
infected, MAC-treated, etanercept-treated group (Enbrel SM) (P < 0.05). TNFα levels in 
cardiac muscle of the SIV-infected, MAC-treated, etanercept-treated group (Enbrel H) 
did not differ significantly from levels in skeletal muscle derived from either group. All 
measurements conducted by densitometric analysis of western blots of myocardial and 
skeletal muscle tissue homogenates. (C) TNFα levels in cardiac muscle of animals from 
the SIV+MAC group (SIV+MAC H) exceeds that in skeletal muscle of the SIV+MAC 
group (SIV+MAC SM), cardiac muscle of the etanercept-treated group (Enbrel H), and 
skeletal muscle of the etanercept-treated group (Enbrel SM). SIV+MAC: SIV-infected, 
M. avium complex (MAC)-treated group; SIV: SIV-infected animals not subjected to 
MAC treatments; SIV+MAC H: heart muscle from SIV+MAC group; SIV+MAC SM: 
skeletal muscle from SIV+MAC group; Enbrel H: heart muscle from SIV-infected, 
MAC-treated, etanercept-treated animals; Enbrel SM: skeletal muscle from SIV-infected, 
MAC-treated, etanercept-treated animals. 
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Figure 4.2 
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Figure 4.3  Plasma sTNFR2 and IL-18 levels correlate significantly with changes in 
ventricular chamber size and systolic function. (A) Plasma sTNFR2 levels rose 
significantly from baseline (P < 0.001) in SIV-infected animals by day 14, corresponding 
to the period of peak viremia, and remained elevated thereafter. Data from etanercept-
treated animals are not included due to cross-reactivity of etanercept itself (a fusion 
protein comprised of the extracellular ligand-binding portion of sTNFR2 bound to the Fc 
portion of human IgG1) with antibodies specific for sTNFR2 in the assay. (B) Plasma IL-
18 levels rose sharply in SIV-infected animals by day 14, reaching levels significantly 
above baseline (P < 0.001), then dropped rapidly back toward pre-infection levels.  (C) 
Plasma levels of sTNFR2 at day 14 correlated significantly with percent change in 
LVEDD at day 35 (P < 0.01, R = 0.578) such that higher plasma sTNFR2 levels were 
associated with greater chamber enlargement at the final time point. (D) Plasma levels of 
IL-18 at day 14 also correlated significantly with percent change in LVEDD at day 35 (P 
< 0.05, R = 0.407), with higher plasma IL-18 being associated with greater chamber 
enlargement at the final time point. (E) Plasma IL-18 levels at day 0 correlated 
significantly with percent change in LVEF at day 35 (P < 0.05, R = 0.445), such that 
higher baseline IL-18 levels were associated with greater preservation of ejection fraction 
at the terminal time point. SIV+MAC: SIV-infected, M. avium complex (MAC)-treated 
group; SIV: SIV-infected animals not subjected to MAC treatments; SIV+MAC+Enbrel: 
SIV-infected, MAC-treated, etanercept-treated animals; MAC: uninfected, MAC-treated 
controls. 
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Figure 4.3 
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Figure 4.4.  Myocardial iNOS levels, plasma viral load, myocardial SIV-infected cell 
burden, and peripheral CD4 T cell count do not correlate significantly with changes 
in ventricular chamber diameter or systolic function. (A) Myocardial iNOS levels 
were significantly lower (*) in the MAC control group than in the SIV+MAC group (P < 
0.05), but did not significantly differ among SIV-infected groups and did not correlate 
with any evaluated echocardiographic parameter. (B) Plasma viral loads in the SIV-
infected, MAC-treated, etanercept-treated group, which experienced no significant 
echocardiographic changes, were significantly higher than in the SIV+MAC group, in 
which prominent structural and functional changes developed (P < 0.05). (C) SIV-
infected cells within myocardial tissue were rare and their presence and number did not 
correlate with any evaluated echocardiographic parameter (SIV nef 
immunohistochemistry with Mayer’s hematoxylin. Micron bar = 50 μm). (D) Animals in 
SIV-infected groups developed significant decreases in CD4 T cell counts relative to the 
uninfected MAC control group (P < 0.01); however, CD4 counts did not correlate 
significantly with any measure of systolic function or ventricular chamber size. 
SIV+MAC: SIV-infected, M. avium complex (MAC)-treated group; SIV: SIV-infected 
animals not subjected to MAC treatments; SIV+MAC+Enbrel and Enbrel: SIV-infected, 
MAC-treated, etanercept-treated animals; MAC: uninfected, MAC-treated controls. 
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Figure 4.4 
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5.1 Introduction 
 Understanding mechanisms and root causes of disease is necessary to guide 
intelligent design of therapies and preventative strategies. HIV-associated myocardial 
disease has been recognized since the early years of the pandemic, but has remained a 
poorly understood phenomenon with many possible contributors. Better defining features 
specific to etiology of the condition is important to optimization of efforts at prevention 
and treatment. Furthermore, HIV infection provides a defined venue for exploring 
fundamental roles for chronic immune activation and host inflammatory response in the 
development and progression of myocardial injury, features which have substantial 
relevance beyond the context of HIV-associated disease alone. 
 
5.2 Summary of Central Findings 
Cardiomyopathy and lymphocytic myocarditis have been frequently documented 
among chronically SIV-infected rhesus monkeys, providing an excellent model system 
for study of HIV-associated cardiac disease [178].  Initial studies reported here [158, 159] 
focus on identifying correlates of lymphocytic inflammation, assessing possible causes of 
the inflammation, and the likelihood of inflammation as an underlying causative factor 
for development of SIV-associated cardiomyopathy [68-70]. While inflammatory lesions 
are indeed common, careful review finds them to be typically quite mild. This finding is 
in agreement with descriptions from the HIV literature, where the mildness of lesions is 
commonly attributed to the profound immunodeficiencies which occur in late stage 
infection. Given this mild character, however, it is difficult to attribute significant 
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functional or structural consequences to the inflammation itself, particularly in the 
absence of any demonstrable association between extent of inflammation and extent of 
cardiomyocyte necrosis, cardiomyocyte apoptosis, myocardial fibrosis, contractile 
dysfunction or ventricular remodeling. This lack of association supports the hypothesis 
that factors other than direct cardiomyocyte damage resulting from infiltrating 
lymphocyte populations may be responsible for the development of cardiac dysfunction 
in HIV/SIV infection. Intramyocardial SIV-infected cells also do not appear likely to play 
any direct role in cardiac disease pathogenesis given their rarity and lack of significant 
correlations with evaluated histomorphologic or functional pathologies.  In contrast, two 
subsets of macrophages present in very high numbers throughout the myocardial 
interstitium and perivascular tissues showed significant correlations variously with extent 
of T cell infiltration, numbers of SIV-infected cells, and endothelial MHC class II 
expression, as well as having numbers which differed dramatically between SIV-infected 
groups as a function of the presence or absence of lymphocytic inflammation. The wide 
distribution of macrophage populations throughout the myocardium uniquely situates 
them to assert global effects on myocardial function via actions of secreted soluble 
mediators. Macrophages characterized by expression of the antigens DC-SIGN and 
CD163 were found in high numbers in hearts from SIV-infected animals without 
inflammation, were excluded from or occurred only in very low numbers within 
inflammatory clusters, and were positively correlated with numbers of SIV-infected cells. 
Both DC-SIGN and CD163 have been reported to be upregulated in environments rich in 
TH2-type cytokines and down-regulated in the presence of LPS or TNFα, consistent with 
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markers of non-classical activation [192, 208, 213, 224, 225]. Specifically, IL-4 and IL-
13 have been demonstrated to upregulate DC-SIGN [192, 225, 226], while IL-10 and IL-
6 upregulate CD163 [208, 213, 224]. A single report has also found upregulation of DC-
SIGN in vitro on stimulation with IL-10, and in vivo in tissue having a high IL-10/IL-12 
ratio, suggesting the possibility of a single microenvironment in which both antigens 
might be found in abundance [227]. Given that MHC class II expression has been 
reported to be down-regulated in IL-10-rich contexts [228-230], high levels of 
myocardial  IL-10 could potentially explain the correlation identified between numbers of 
DC-SIGN+ cells and loss of endothelial MHC class II [158]. In addition, IL-10-mediated 
inhibition of chemokine production [231] could account for the correlation between 
numbers of DC-SIGN+ cells and extent of T cell infiltration. There is conflicting 
evidence as to whether IL-10 enhances or inhibits HIV replication (reviewed in [231]), 
but HIV replication has been documented to be significantly enhanced in macrophages 
which have engaged in phagocytosis of apoptotic debris, an activity which incurs upon 
them a prominently anti-inflammatory phenotype [232-234].  CD163+ macrophages have 
been associated with an anti-inflammatory phenotype, including IL-10 secretion on 
ligand-binding, inhibition of lymphocyte proliferation, and decreased expression of 
lymphocyte activation markers [175, 202, 208-210].  Cross-linking of DC-SIGN, a C-
type lectin which serves as a broad-spectrum pathogen receptor (reviewed in [235]), has 
also been associated with high IL-10 production in the context of concurrent TLR2, 
TLR4, or  TNFα stimulation in vitro, significantly modulating the cellular response to 
otherwise inflammatory stimuli [236]. 
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The findings presented in the first two reports provide initial evidence that 
myocardial antigen presenting cell populations might be significantly associated with 
induction or suppression of local myocardial inflammatory responses, expression of 
antigens by local, non-leukocyte populations, and quite possibly functional effects on 
cardiomyocytes, through properties of secreted cytokines. More extensive evaluation of 
the cytokine milieu of the myocardial microenvironment will provide an important 
starting point for future work. 
Given the paucity of literature examining tissue macrophage subsets in the 
context of HIV/SIV infection, the extent to which the patterns identified in myocardium 
in current work may also characterize other tissues in HIV/SIV-infection is unknown. In 
health, certain tissues are known to contain native macrophage populations with non-
classical properties. The lamina propria of the intestine for instance, contains a large 
population of macrophages which do not produce inflammatory cytokines, do not present 
antigen, and lack many innate immune receptors, but which engage in high efficiency 
phagocytosis and microbial killing [237]. Similarly, pulmonary alveolar macrophages in 
the steady state constitutively express DC-SIGN, constitutively secrete IL-10 and 
constitutively express the IL-10 receptor, though they are capable of responding with 
vigorous inflammatory responses when appropriately stimulated [238].  
In the context of SIV infection, one group has found expansion of the 
CD163+/CD16+ monocyte population in peripheral blood, with degree of expansion 
correlating significantly with viral load [239]. Another group has found perivascular 
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macrophages in both normal and encephalitic brains from HIV- and SIV-infected 
individuals to be uniformly CD163 positive, with increased numbers of CD163+ cells 
associated with encephalitic lesions [216]. Interestingly however, in case selection for 
this study, brains that had significant lymphocytic infiltration were omitted from 
consideration (S. Westmoreland, pc) such that any potential distinction in CNS 
macrophage phenotype associated with the presence or absence of lymphocytic 
inflammation will not have been identified. To the author’s knowledge, no work aside 
from that presented here has been published which specifically examines differences in 
macrophage subsets in tissues in the context of HIV/SIV infection and the possible 
consequences of those differences. 
In the final report [240], an acute SIV infection model employing recurrent 
antigenic stimulation with whole, heat-killed Mycobacterium avium complex (MAC) 
bacteria assesses the effects of experimentally augmented immune activation on 
myocardial structure and function, in order to directly examine the possibility of a role 
for inflammatory cytokines in development of HIV/SIV-associated cardiac disease.  
 In this model, SIV-infected animals developed marked myocardial dysfunction 
and structural change in response to antigenic stimulation that was not found in controls, 
and which was preventable by concurrent administration of a TNFα antagonist. This 
fundamentally different myocardial response to systemic antigenic stimulation in SIV-
infected animals, with the appearance of delayed and progressive structural and 
functional pathology after cessation of the stimulus, was associated with myocardium-
specific elevations in TNFα that were significantly higher in antigenically stimulated 
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SIV-infected animals than in unstimulated SIV-infected animals.  Ventricular structural 
change correlated with markers of systemic immune activation as indicated by significant 
relationships between circulating plasma levels of sTNFR2 and IL-18 at the time of peak 
viremia and extent of left ventricular dilatation at the terminal time point. In contrast, 
decreases in systolic function showed a significant association not with increased 
immune activation at peak viremia, but with baseline levels of IL-18, a finding which is 
intriguing given recent studies identifying significant relationships between baseline IL-
18 levels and risk of future coronary events [241], myocardial infarction [242], and 
cardiovascular mortality [243-245], even among large cohorts of healthy men [241].   
 
5.3 Increased Risk of Disease Development in the Context of Microbial 
Co-infections 
 Findings reported here imply that significant exposure to antigens from non-
HIV/SIV microbial agents, such as occurs in later stages of HIV/SIV infection as immune 
competence fails, is likely to substantially enhance the probability of cardiac disease 
development and progression. This finding is consistent with the often noted observation 
that HIVCM is strongly associated with depressed CD4 T cell counts and advanced 
infection [30, 38, 39]. Based on experimental findings in our model, this association may 
in part be a product of TNFα-mediated myocardial hyperresponsivity to antigenic 
stimulation. 
Mycobacterium avium complex bacteria are environmentally ubiquitous and 
disseminated M. avium infection is one of the most frequent opportunistic infections in 
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both human and simian AIDS [218-220, 246]. Furthermore, primary macrophages from 
HIV-infected people have been demonstrated to produce significantly higher levels of 
both TNFα and IL-1β on stimulation with M. avium than macrophages from uninfected 
control individuals [142]. Exaggerated inflammatory cytokine production by 
macrophages from HIV-infected people on exposure to common opportunists such as M. 
avium, particularly in the face of the very high bacterial loads that develop in HIV-
infected individuals with disseminated disease, may provide one explanation for the 
common occurrence of HIV-associated cardiac disease in later stages of disease 
progression, particularly given our current evidence for myocardial TNFα autoinduction, 
as this suggests that increased systemic levels of TNFα may undergo local amplification 
within the myocardium.  
 Co-infection with pathogens other than HIV and stimulation with non-HIV 
microbial antigens has been implicated in many reports to contribute to adverse outcomes 
in the context of HIV infection, through increased susceptibility to initial infection [247, 
248], increased rate of disease progression [83, 247, 248], increasing levels of viral 
replication [142, 249-252], and overall enhanced development of further opportunistic 
infections and shortened survival [253]. Furthermore, recent investigations in a murine 
model of AIDS-associated cardiomyopathy have demonstrated that subseptic 
lipopolysaccharide (LPS) exposure resulted in cardiac dysfunction, ventricular 
hypertrophy, and ventricular chamber dilatation in infected mice, similar to our findings 
with administration of inactivated whole mycobacteria, and found these changes to be 
significantly associated with increased levels of non-focal myocardial macrophage 
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infiltration as well as increased levels of TLR4 expression, implicating a role for 
macrophage involvement and toll-like receptor signaling in development of the observed 
pathology [171]. 
 
5.4 Anti-TNFα Biologics as Therapeutic Agents: Heart Failure and HIV 
Infection 
 While usage of the TNFα antagonist etanercept clearly demonstrated the TNFα 
dependence of the myocardial changes observed in antigenically stimulated SIV-infected 
animals by preventing development of systolic dysfunction and left ventricular dilatation,  
etanercept use was also associated with significantly increased plasma viral loads, 
suggesting that interference with the TNFα response at these early time points, while 
protective to the myocardium, resulted in reduced control of viral proliferation. Use of 
anti-TNFα therapies such as etanercept has been associated with increased risk of a wide 
variety of infections [254-256], and because of this and the risk of potentially worsening 
disease progression in HIV-infected individuals, usage of anti-TNFα therapies in HIV-
infected people has been infrequently reported. Nevertheless, the majority of reports 
describing use of anti-TNFα biologics in HIV-infected people describe no significant 
changes in viral load, no clinical deterioration, and no occurrence of significant 
opportunistic infections even over periods of therapy lasting greater than 4 years [257-
264].  However, as substantial evidence suggests that devastating immunologic damage 
takes place very early post-infection [265], it is possible that etanercept treatment during 
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the early acute infection period, as in our experimental model, might be associated with 
more deleterious outcomes as a result of diminished early viral containment than perhaps 
would be seen in similarly treated individuals with established, stable infections. Given 
the small number of cases reported in the literature to this point, however, the safety of 
anti-TNFα therapies in HIV-infected individuals overall requires further evaluation. 
Numerous clinical trials evaluating the utility of anti-TNFα therapies in heart 
failure treatment have been conducted in recent years based on the considerable evidence 
in support of a role for inflammatory cytokine involvement in progression of heart 
failure. However, while small, short-term early trials yielded promising improvements in 
outcome [266, 267], large multicenter randomized double-blind trials have uniformly 
yielded disappointing results [268, 269] (reviewed in [270]). While the reasons for this 
failure are matters of ongoing debate, current evidence suggests that anti-TNFα treatment 
for existing heart failure is of no benefit and in some cases may actually worsen 
outcomes [269, 271]. Whether there are circumstances under which anti-TNFα regimens 
could be employed therapeutically to prevent development of heart failure, as is 
suggested by our experimental results, is as yet an open question. 
 
5.5 Conclusions 
The current studies report work examining potential roles for myocardial 
macrophages and inflammatory cytokines in susceptibility to HIV/SIV-associated 
myocardial pathology. Previous work examining roles for inflammatory cytokines in the 
development and progression of HIV-associated cardiac disease has been very limited, 
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and the possibility of a role for antigenic stimulation in generation of these tissue-specific 
cytokine-dependent myocardial responses has not previously been explored. Many 
possible environmental, viral, and host factors have previously been identified as possible 
contributors to development of HIV-associated cardiac disease, including direct 
myocardial infection by cardiotropic and opportunistic pathogens, anti-cardiac 
autoimmunity, drug-induced cardiotoxicity, cardiodepressant viral proteins, and 
micronutrient deficiencies, all of which may in some circumstances play contributory 
roles. Given the complexity of the many interacting features in late-stage HIV infection, 
it is unlikely that a single etiology will suffice to encompass all cases of cardiomyopathy 
that arise in affected populations. However, findings from the current studies suggest that 
characteristics of local myocardial macrophage populations and the local myocardial 
cytokine milieu may play more important roles than lymphocytic infiltration, direct 
cardiomyocyte damage, or viral proteins in the pathogenesis of HIVCM, and that the 
exaggerated levels of antigenic stimulation that occur through multipathogen exposures 
in later stages of infection may be sufficient in the HIV-infection context to yield 
progressive myocardial disease.   
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